<SEC-DOCUMENT>0000902664-23-002514.txt : 20230406
<SEC-HEADER>0000902664-23-002514.hdr.sgml : 20230406
<ACCEPTANCE-DATETIME>20230406172459
ACCESSION NUMBER:		0000902664-23-002514
CONFORMED SUBMISSION TYPE:	PRRN14A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20230406
DATE AS OF CHANGE:		20230406

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRRN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		23807204

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Caligan Partners LP
		CENTRAL INDEX KEY:			0001727492
		IRS NUMBER:				822603419
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRRN14A

	BUSINESS ADDRESS:	
		STREET 1:		515 MADISON AVENUE
		STREET 2:		9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		718-570-6018

	MAIL ADDRESS:	
		STREET 1:		515 MADISON AVENUE
		STREET 2:		9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRRN14A
<SEQUENCE>1
<FILENAME>p23-1227prrn14a.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">SCHEDULE 14A</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">Proxy Statement Pursuant to Section 14(a)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">of the Securities Exchange Act of 1934<BR>
(Amendment No. 1)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">Filed by the Registrant
</FONT><FONT STYLE="font-family: Wingdings; font-size: 15pt">o</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 11pt">Filed by a Party other
than the Registrant </FONT><FONT STYLE="font-family: Wingdings; font-size: 15pt">&#254;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Wingdings; font-size: 15pt">&#254;</FONT></TD>
    <TD STYLE="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Wingdings; font-size: 15pt">o</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Wingdings; font-size: 15pt">o</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Wingdings; font-size: 15pt">o</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Wingdings; font-size: 15pt">o</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 11pt">Soliciting Material Under Rule 14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Anika Therapeutics, Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Registrant as Specified In Its Charter)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Caligan Partners LP</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Caligan Partners Master Fund LP</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">David Johnson</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Gary Peter Fischetti</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">James T. Hogan</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Person(s) Filing Proxy Statement, if other
than the Registrant)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt/85% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; line-height: 85%"><FONT STYLE="font-family: Wingdings; font-size: 15pt; line-height: 85%">&#254;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; line-height: 85%"><FONT STYLE="font-size: 10pt; line-height: 85%">No fee required.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; line-height: 85%"><FONT STYLE="font-family: Wingdings; font-size: 15pt; line-height: 85%">o</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; line-height: 85%"><FONT STYLE="font-size: 10pt; line-height: 85%">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; line-height: 85%"><FONT STYLE="font-family: Wingdings; font-size: 15pt; line-height: 85%">o</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; line-height: 85%"><FONT STYLE="font-size: 10pt; line-height: 85%">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 92%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 12pt/85% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center; color: red"><B>PRELIMINARY COPY SUBJECT TO COMPLETION</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>DATED [ ], 2023 </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>ANIKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 9.5pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">32 Wiggins Avenue</P>

<P STYLE="font: 9.5pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">Bedford, Massachusetts 01730</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>__________________________</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>PROXY STATEMENT</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 67px; width: 223px"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Caligan Partners LP</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>_________________________</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>PLEASE SIGN, DATE AND MAIL THE ENCLOSED <U>BLUE</U> PROXY CARD TODAY</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">This Proxy Statement and the enclosed <B><U>BLUE</U></B> proxy card
are being furnished by Caligan Partners LP and certain of its affiliates (as identified on Annex I, &ldquo;Caligan&rdquo;,
&ldquo;we&rdquo; or &ldquo;us&rdquo;), and the two Caligan Nominees (defined below) named in Proposal 1 below in connection with the
solicitation of proxies (the &ldquo;Proxy Solicitation&rdquo;) from the stockholders of Anika Therapeutics, Inc., a Delaware
corporation (&ldquo;Anika&rdquo; or the &ldquo;Company&rdquo;), to elect our highly qualified Caligan Nominees to the Board of
Directors of the Company (the &ldquo;Board&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">According
to the Company&rsquo;s [preliminary] proxy statement (the &ldquo;Company&rsquo;s Proxy Statement&rdquo;) for the upcoming 2023 annual meeting
of stockholders (the &ldquo;Annual Meeting&rdquo;), the Annual Meeting will be conducted virtually via live audio webcast on [&#9679;],
2023 at [&#9679;] Eastern Time, unless adjourned or postponed to a later date. Each holder of common stock, par value $0.01 per share
(&ldquo;Common Stock&rdquo;) as of 5:00 p.m., Eastern time, on the Record Date of [&#9679;], 2023 (the &ldquo;Record Date&rdquo;) will
be able to participate in the Annual Meeting by accessing a live audio webcast at <I>www.cesonlineservices.com/anik23_vm</I>. According
to the Company&rsquo;s Proxy Statement, to participate in the Annual Meeting, you must pre-register at </FONT><FONT STYLE="font-size: 10pt">www.cesonlineservices.com/anik23_vm
</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">by [</FONT>&#9679;<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">],
Eastern Time, on [&#9679;], 2023.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We believe that while Anika has tremendously valuable assets,
                                                                    Anika has not been a successful investment for stockholders and, as explained below, we believe that the Board&rsquo;s poor
                                                                    oversight of business development initiatives, with respect to its 2020 acquisitions of Arthrosurface and Parcus, and the significant
                                                                    financial losses associated with the joint preservation segment, have caused Anika&rsquo;s share price decline. We believe the
                                                                    Caligan Nominees will bring a much-needed stockholder voice, as well as experience, financial discipline and accountability to the
                                                                    current Board. We are therefore seeking your support and soliciting your proxies with respect to the following (each, a
                                                                    &ldquo;Proposal&rdquo; and, collectively, the &ldquo;Proposals&rdquo;):</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B>&nbsp;&nbsp;Proposal</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B>Our Recommendation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 76%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DBE5F1">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To elect Caligan&rsquo;s slate of two nominees &mdash; Gary Peter Fischetti and James T. Hogan (each, a &ldquo;Caligan Nominee&rdquo; and collectively, the &ldquo;Caligan Nominees&rdquo; and, together with Caligan, the &ldquo;Participants&rdquo;) &mdash; to serve as Class III directors and hold office until the annual meeting of stockholders to be held in 2026 and until their respective successors are duly elected and qualified.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>FOR </B>all of the Caligan Nominees</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DBE5F1">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD>&nbsp;<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Ratification of appointment of Deloitte &amp; Touche LLP as Anika&rsquo;s independent auditor for 2023.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>FOR</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DBE5F1">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Advisory &ldquo;say-on-pay&rdquo; vote on executive compensation.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>AGAINST </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DBE5F1">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Advisory &ldquo;say-on-frequency&rdquo; vote on the frequency of future advisory votes on executive compensation.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>ONE YEAR</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DBE5F1">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #DBE5F1">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To transact other business as may properly come before the Annual Meeting.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The Board is currently composed of seven directors divided into three classes
in accordance with a &ldquo;classified&rdquo; structure pursuant to the Certificate of Incorporation of the Company, as amended (the
&ldquo;<U>Charter</U>&rdquo;). According to the Company&rsquo;s Proxy Statement, there will be two directors elected at the Annual Meeting.
Through this Proxy Statement and enclosed <B><U>BLUE</U></B> proxy card, we are soliciting proxies to elect the Caligan Nominees named
herein to serve as directors, who, if elected, would only constitute a minority of the Board. There is no assurance that any of the Company&rsquo;s
remaining incumbent directors will continue to serve as directors if any or all of the Caligan Nominees are elected.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">[At the close of business on the Record Date, there were [&#9679;] of shares
of Common Stock outstanding according to the Company&rsquo;s Proxy Statement.] Stockholders of record at the close of business on the
Record Date will be entitled to vote at the Annual Meeting. As of [&#9679;], 2023, the Participants beneficially owned [726,161] shares
of Common Stock in the aggregate, together representing approximately [&#9679;]% of the outstanding shares of Common Stock of the Company,
as further described in Annex I.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We urge you to use Caligan&rsquo;s enclosed <B><U>BLUE</U></B> proxy card
to vote by telephone or the Internet by following the instructions on Caligan&rsquo;s <B><U>BLUE</U></B> proxy card. Your vote is important,
and we are encouraging stockholders to submit their proxies electronically if possible. Alternatively, if you do not have access to a
touch-tone telephone or the Internet, please sign, date and return Caligan&rsquo;s <B><U>BLUE</U></B> proxy card in the postage-paid
envelope provided. Please vote <B>&ldquo;FOR&rdquo; </B>all of the Caligan Nominees to the Board and to <B>&ldquo;WITHHOLD&rdquo; </B>on
John B. Henneman, III (&ldquo;Mr. Henneman&rdquo;) and Susan L. N. Vogt (&ldquo;Ms. Vogt&rdquo; and, together with Mr. Henneman, the
&ldquo;Opposed Company Nominees&rdquo;) with respect to Proposal 1, <B>&ldquo;FOR&rdquo;</B> Proposal 2, <B>&ldquo;AGAINST&rdquo; </B>Proposal
3 and <B>&ldquo;ONE YEAR&rdquo;</B> for Proposal 4.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The Participants represent that (i) they intend to, or are part of a group
which intends to, deliver a proxy statement and form of proxy to holders of at least the percentage of the Company&rsquo;s outstanding
capital stock required to elect the Caligan Nominees at the 2023 Annual Meeting, and (ii) they intend to, or are part of a group which
intends to, solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of
directors in support of the Caligan Nominees.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">This Proxy Statement and <B><U>BLUE</U></B> proxy card are first being mailed or given to
the Company&rsquo;s stockholders on or about [ ], 2023.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>WE URGE YOU TO ACT TODAY TO ENSURE THAT YOUR VOTE
WILL COUNT.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We urge you to sign, date and return the <B><U>BLUE</U></B> proxy card
and to vote <B>&ldquo;FOR&rdquo;</B> all of the Caligan Nominees and to <B>&ldquo;WITHHOLD&rdquo;</B> on the Opposed Company
Nominees with respect to <U>Proposal 1</U>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>This Proxy Solicitation is being made by Caligan and the Caligan Nominees,
and not on behalf of the Board or management of the Company or any other third party. </B>We are not aware of any other matters to be
brought before the Annual Meeting other than as described herein. Should other matters be brought before the Annual Meeting, the persons
named as proxies in the enclosed <B>BLUE</B> proxy card will vote on such matters in their discretion.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>If you have already voted using the Company&rsquo;s white proxy card,
you have every right to change your vote by completing and mailing the enclosed <U>BLUE</U> proxy card in the enclosed pre-paid envelope
or by voting via Internet or by telephone by following the instructions on the <U>BLUE</U> proxy card. </B>Only the latest validly executed
proxy that you submit will be counted; any proxy may be revoked at any time prior to its exercise at the Annual Meeting by following the
instructions under &ldquo;Can I change my vote or revoke my proxy?&rdquo; in the Questions and Answers section.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For instructions on how to vote and other information about the proxy
materials, see the Questions and Answers section starting on page [&#9679;].</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: #365F91; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0 0 1pt; text-align: center; color: white"><B>We urge you to promptly sign,
    date and return your <U>BLUE</U> proxy card.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>If you have any questions or require any
assistance with voting your shares, please contact our proxy solicitor, D.F. King &amp; Co., Inc. (&ldquo;D.F. King&rdquo;), toll
free at (800) 431-9643 or by email at ANIK@dfking.com<SUP></SUP>.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>BACKGROUND OF THIS PROXY SOLICITATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I>Reasons for this Solicitation</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Caligan believes Anika represents an attractive, long-term investment
opportunity due to its market-leading viscosupplement portfolio, Monovisc and Orthovisc, and efficient commercialization strategy with
those assets, but that Anika is in urgent need of change for reasons related to two key factors:</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I><U>1. Investor Concern Over the Company&rsquo;s Joint Preservation
and Restoration (&ldquo;JP&rdquo;) Segment</U></I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Anika&rsquo;s financials demonstrate that Anika&rsquo;s JP Segment is operating
at a ~$40MM loss annually.<SUP>1</SUP> We calculate that, just for the segment to break even, Anika would need to grow JP revenue by
215%, with no incremental operating expense.<SUP>2</SUP> This implies losses for more than a decade for a segment that the Company has
guided to grow 10-15% in 2023 with the majority of the growth &ldquo;weighted more toward the second half of this year.&rdquo;<SUP>3</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I><U>2. Loss of Investor Confidence Due to Consistent</U></I><U> <I>JP
Segment Misses and Withdrawn 2024 Guidance</I></U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">At its 2021 Investor Day, more than a year after the COVID-19 pandemic&rsquo;s
impact to its business were well-known, Cheryl R. Blanchard, Ph.D., the Company&rsquo;s President and Chief Executive Officer (&ldquo;Dr.
Blanchard&rdquo;), conveyed management&rsquo;s revenue and EBITDA targets, which implied doubling FY2019&rsquo;s revenue and a 20% adjusted EBITDA
margin by 2024.<SUP>4</SUP> By March 2022, not even 9 months later, management withdrew these 2024 targets. Anika&rsquo;s shares fell
-14.3% on March 9, 2022, the day after withdrawing the 2024 guidance, underperforming the XBI by -19.2%.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">After the Company&rsquo;s 4Q2022 earnings call, a sell-side analyst
remarked, &ldquo;we find both targets as unlikely to be achieved and impossible to try to prove at this point given the material
deterioration in the company&rsquo;s financials over the past few years.&rdquo;<SUP>5</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Similarly damaging to management credibility and a further indictment
of the quality of the JP segment and management&rsquo;s ability to accurately forecast it, Anika has had to cut its initial guidance
every single year in the JP segment since the Company acquired Arthrosurface and Parcus.<SUP>6</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B><I>Due To The Strategic Pivot, Anika Has Materially Underperformed
its Peer Group</I></B><I><SUP>7</SUP> <B>and Broader Indices. </B></I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">Despite its well-capitalized balance sheet, with ~$90MM in cash,
no debt, and positive adjusted EBITDA, Anika&rsquo;s total shareholder return (&ldquo;TSR&rdquo;) has underperformed both its self-selected
peer group<SUP>8</SUP> and broader indices over all relevant time horizons, specifically since the Company announced a strategic pivot in September
2019 and since Dr. Blanchard became CEO in February 2020.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">&nbsp;_______________________________________<BR>
<SUP>1 </SUP>Caligan estimates that the JP segment has ~$61MM in operating expenses
(based on a calculation of Anika&rsquo;s 2022 GAAP operating expenses less Anika&rsquo;s 2019 GAAP operating expenses). Assuming the JP
segment has a 44% gross margin, this would require $139MM in revenue ($61 / 0.44) in order to generate enough gross profit to cover the
JP segment operating expenses. The Company&rsquo;s JP revenue of $50.4MM, less Caligan&rsquo;s estimate of $6MM in revenue of Tactoset,
a legacy product based on the Company&rsquo;s hyaluronic acid technology platform, is ~$44MM for 2022. The incremental $95MM of revenue
represents a 215% increase over the Company&rsquo;s 2022 revenue.</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>2 </SUP>Id.</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>3</SUP> S&amp;P Capital IQ. 4Q2022 earnings transcript.</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>4 </SUP>Dr. Cheryl Blanchard, 2021 Investor Day Transcript, S&amp;P
Capital IQ. Dr. Blanchard stated that the Company expects to &ldquo;double our 2019 revenue in mid-teens revenue CAGR, driving to an adjusted
gross margin that expands to greater than 70% and double-digit adjusted EBITDA growth run rate by 2024, which gets us to a greater than
20% adjusted EBITDA margin.&rdquo;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>5</SUP> Barrington research report March 7, 2023. </P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>6</SUP> S&amp;P Capital IQ. Earnings transcripts 4Q2019, 1Q2020 withdrawing
guidance altogether. 4Q2020, Company expected full year joint preservation revenue growth in &ldquo;upper 20s to low 30s percent range&rdquo;,
in 3Q2021, guidance reduced to &ldquo;upper teens&rdquo;. In 4Q2021, guidance was for &ldquo;mid-single digits to low teens&rdquo; and
in 3Q2022, guidance for JP was lowered to &ldquo;low to mid -single digit.&rdquo;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>7 </SUP>Anika peer group as disclosed on page 48 of the Company&rsquo;s
Proxy Statement; S&amp;P Capital IQ.</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>8 </SUP>As disclosed on page 48 of the Company&rsquo;s Proxy Statement.
</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 390px; width: 900px"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0">Source:
S&amp;P Capital IQ, Bloomberg</P>

<P STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0"><SUP>1</SUP> As of August 15, 2022, the day which
Caligan began accumulating shares of Anika</P>

<P STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0"><SUP>2</SUP> Dr. Blanchard became CEO on February
10, 2020</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Anika&rsquo;s EV/revenue multiples are significantly below proxy peers&mdash;just
1.6x FY2023 consensus revenue estimates<SUP>9</SUP>&mdash;reflecting what we interpret is the public markets&rsquo; deeply cautious view
of Anika&rsquo;s present and future prospects. Four years ago, when Johnson &amp; Johnson (&ldquo;J&amp;J&rdquo;) represented more than
70% of Anika&rsquo;s total revenues, Anika traded at a 3% valuation premium to its medical device peer group.<SUP>10</SUP></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">After the Company announced a new strategy of using cash flows from
                                                                                                             J&amp;J to fund a strategic pivot into JP at its September 2019 Investor Day, <B><U>Anika&rsquo;s forward revenue trading multiple
                                                                                                             started to collapse, dropping ~68%. As of August 2022, the Company traded at a ~60% discount to its peers</U></B>.<SUP>11</SUP>
                                                                                                             We believe that due to the low quality and high resource intensity of the assets Anika acquired, investors have punished
                                                                                                             Anika&rsquo;s attempts to diversify with a lower trading multiple.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-right: 0; margin-left: 0"><B><I>We believe that Anika&rsquo;s
Viscosupplement Portfolio Will Not Be Appropriately Valued by Public Markets.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-right: 0; margin-left: 0">We believe:&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Anika&rsquo;s public disclosure surrounding its viscosupplement products is
opaque, which we believe causes the public markets to struggle to appropriately value the segment. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">This
is because Anika commingles its financial reporting of a high margin royalty stream from the osteoarthritis pain management segment (OA
Segment) with the revenues, development, and commercial infrastructure costs of the JP segment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">The
upside in addressing the losses in the JP segment is considerable and indicates that <B><U>Anika can be worth ~$59 per share, more than
double the current share price, by exiting the JP segment and removing the associated losses</U></B>.<SUP>12</SUP></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0"><SUP>_______________________________________<BR> 9 </SUP><FONT STYLE="font-size: 9pt">S&amp;P
Capital IQ, as of August 15, 2022, the day which Caligan began acquiring shares of Anika.<SUP>&nbsp;</SUP></FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>10 </SUP>ANIK&rsquo;s medical device proxy peers defined as GKOS, ORGO,
SRDX, VCEL, OFIX, AXGN, ATRC, AORT.</P>




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>11 </SUP>Figures as of August 15, 2022.</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>12</SUP> See Caligan&rsquo;s letter to the Board, dated February 21, 2023, filed
on February 21, 2023 with the SEC as soliciting material under cover of Schedule 14A. Caligan estimates that the ~$68MM of revenue from
J&amp;J would be valued at a 10% discount rate in perpetuity, representing $685MM in value; there is ~$86MM of cash on the Company&rsquo;s
balance sheet and Caligan estimates the non-US viscosupplement revenue (~$30MM) would be valued at a 20% discount rate or 5x capitalization
rate, or ~$150MM of value. The sum of these is ~$915MM of value, divided by 15.4 million shares outstanding (including unvested restricted
stock units and the dilutive effect of options), is ~$59 per share.</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>&nbsp;</SUP></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0"><B><I>The Path Forward.</I></B></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">We believe that that the status quo is untenable and that urgent changes&mdash;including
a strategic review on how to realize the full potential of Anika&rsquo;s most valuable assets&mdash;are needed. We believe our two Caligan
Nominees would bring to the board fresh perspectives and decades of experience creating value in the medical device and pharmaceutical
industries.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>We urge shareholders to vote &ldquo;FOR&rdquo; both of the
Caligan Nominees today by signing, dating and returning a <U>BLUE</U> proxy card.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Jim Hogan (&ldquo;Mr. Hogan&rdquo;) has held senior leadership
positions at Medtronic and Pfizer and has also founded three medical device companies. Over the course of his career, Mr. Hogan has had
direct responsibility for all disciplines within medical device companies including commercialization, operations, manufacturing, finance
and accounting, regulatory affairs, clinical trials, human capital, legal affairs, and research and development, which makes him well-suited
to thoroughly evaluating the Company&rsquo;s joint preservation product positioning and the ongoing financial losses with a fresh perspective.&nbsp;
We believe he will ensure that the Company is prioritizing the highest return on investment opportunities, including the Company&rsquo;s
own shares.&nbsp; We also believe he is better suited to evaluate the Company&rsquo;s standalone prospects versus alternatives than the
current directors, who, in Caligan&rsquo;s opinion, are entrenched in their strategic direction, despite the value destruction suffered
by shareholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Arial, Helvetica, Sans-Serif">Gary Fischetti (&ldquo;Mr. Fischetti&rdquo;) is well positioned to evaluate
the Company&rsquo;s viscosupplement portfolio, development assets, and strategic relationship with the Company&rsquo;s largest customer,
Mitek, given his prior experience.&nbsp; Mr. Fischetti has deep experience in evaluating business investments, balancing the tension between
short-term profitability and long-term growth.&nbsp; We believe he will critically evaluate the Company&rsquo;s joint preservation spending
to ensure that Anika&rsquo;s shareholders&rsquo; capital is being deployed appropriately.&nbsp; We believe Mr. Fischetti is well suited,
without personal relationships with the current CEO, to hold management accountable for the financial and operational performance of the
Company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B><I>Background to this Solicitation</I></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Throughout the late summer 2022, David Johnson, Managing Partner of Caligan
(&ldquo;Mr. Johnson&rdquo;), spoke with representatives of the Company regarding the Company&rsquo;s business, quarterly results, and
long-term strategy.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On September 23, 2022, Caligan issued a letter to the Board summarizing its thesis for value enhancement at the Company. In the letter, Caligan (i) detailed the ways in which
the Company has consistently meaningfully underperformed, both on an absolute and relative basis as compared against its peers and broader
indices; (ii) described its thesis for the reasons for such underperformance&mdash;namely, concern from the Company&rsquo;s investors
regarding the differentiation of the Company&rsquo;s joint preservation products and the magnitude of losses the Company was suffering;
and (iii) offered potential solutions, including royalty monetization of the viscosupplement business, eliminating low-return R&amp;D
and demonstrating expense discipline, engaging with financial sponsors to see if they could provide a meaningful premium to current shareholders,
and board refreshment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On October 5, 2022, following negotiations between the parties, the Company
and Caligan entered into a limited duration confidentiality agreement with a standstill provision and a term ending on November 5, 2022,
which term was subsequently amended to end on November 10, 2022.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On October 13, 2022, Dr. Blanchard and two other Company representatives
met with Mr. Johnson, who presented three potential paths forward for the Company: (1) reduce spending on the Joint Preservation and Restoration
products&#894; (2) pursue a royalty transaction on the J&amp;J relationship&#894; and (3) explore a &ldquo;sale&rdquo; or &ldquo;going
private&rdquo; transaction.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On November 3, 2022, Dr. Blanchard and other Company representatives spoke
with Mr. Johnson and discussed the Company&rsquo;s financial results for its
recently completed quarter. As part of these discussions, Mr. Johnson also requested an opportunity to talk with members of the Board.<SUP></SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On November 18, 2022, Dr. Blanchard and other Company representatives spoke
with Mr. Johnson and discussed the Company&rsquo;s financial results for its recently completed quarter. During this discussion, Mr.
Johnson reiterated points that he had previously made to the Company about its share price underperformance, the losses in the joint preservation
segment that were not delivering the promised growth, including given the Company&rsquo;s own 2022 guidance, and that public markets were
not appropriately reflecting Anika&rsquo;s intrinsic value.</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Also on November 18, 2022, in an effort to help increase the Company&rsquo;s
visibility with public market investors, Mr. Johnson offered the Company an introduction to a sell-side analyst at Craig-Hallum, who
Mr. Johnson said covered some of the Company&rsquo;s competitors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On December 20, 2022, Jeffrey S. Thompson, the Chair of the Board
(&ldquo;Mr. Thompson&rdquo;), Ms. Vogt, the Chair of the Governance and Nominating Committee of the Board, Dr. Blanchard, and other
Company representatives met with Mr. Johnson. At this meeting, Mr. Johnson made a presentation to the Company that reiterated
Caligan&rsquo;s desire for the Company to: (1) reduce spending on Joint Preservation and Restoration products and return capital to
shareholders&#894; and (2) explore a sale or going private transaction. At the meeting, Mr. Johnson recommended for the
Company&rsquo;s consideration a candidate that at the time Caligan believed would be additive to the Board. This candidate was
subsequently interviewed by the Company on several occasions. During the course of the discussions, neither Mr. Thompson nor Ms.
Vogt acknowledged the substantial value destruction that the joint preservation pivot had caused Anika shareholders, simply
reiterating that they were not prepared to change strategy and that they believed revenue growth was the key to value creation for
Anika, despite the fact that Mr. Johnson repeatedly pointed out that their own projections were for their low-growth viscosupplement
portfolio to grow faster than their joint preservation business in 2022. Mr. Johnson also presented an analysis showing that the
Company had not once met their initial annual public forecasts for the joint preservation business.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On February 8, 2023, Dr. Blanchard and other Company representatives engaged
with Mr. Johnson in a friendly discussion regarding potential strategic alternatives for the Company, including Board refreshment, creating
a board committee, and a $40 million stock repurchase. Dr. Blanchard responded that she would share their conversation with the Board.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On February 16, 2023, Ms. Vogt, Dr. Blanchard, and other Company representatives
rejected all of Caligan&rsquo;s suggestions and represented that they did not want to repurchase stock because they were worried about
the macroeconomic environment, that they would not appoint Caligan&rsquo;s proposed candidate to the Board immediately, and that they
would not create a strategy and capital allocation committee.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On February 21, 2023, Caligan issued a public letter to the Board reiterating
its belief that the Company had underperformed since its strategic pivot to joint preservation due to the heavy losses incurred, that
its viscosupplement portfolio was undervalued and that the Company should consider strategic alternatives and consider Board refreshment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On March 3, 2023, Caligan&rsquo;s legal counsel served a books and records
demand upon the Company pursuant to Delaware General Corporation Law 8 <I>Del. C.</I> &sect; 220 (&ldquo;Section 220&rdquo;) requesting
access to certain Company books and records to, among other reasons, investigate potential mismanagement and breaches of fiduciary duty
by the Company&rsquo;s officers and directors (the &ldquo;Original Demand&rdquo;), including records that would provide clarity surrounding
what Caligan believes was the Company&rsquo;s failure to properly disclose the terminal illness of the Company&rsquo;s previous Chief Executive
Officer, Joseph Darling (&ldquo;Mr. Darling&rdquo;).&nbsp; Specifically, in the Original Demand, Caligan noted the Company&rsquo;s suspicious
behavior in January and February 2020 when the Company stated, on public conference calls, that Mr. Darling was &ldquo;recovering from
a case of laryngitis&rdquo; only to announce several weeks later, not only his untimely passing, but also that the Board apparently knew
of Mr. Darling&rsquo;s terminal illness since early 2019.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Arial, Helvetica, Sans-Serif">On March 10, 2023, the Company&rsquo;s outside counsel refused to produce
a single document in response to Caligan&rsquo;s Demand for reasons which Caligan believes are incorrect, including Caligan&rsquo;s purported
failure to attach documentary proof of Caligan&rsquo;s status as a stockholder to the Original Demand. The Company&rsquo;s outside counsel&rsquo;s
refusal to produce even a single document on this basis was incorrect for at least two reasons. First, &ldquo;[i]n every instance where
the stockholder is <I>other than a record holder of stock</I> in a stock corporation&rdquo; a Section 220 demand must &ldquo;be accompanied
by documentary evidence of beneficial ownership of the stock.&rdquo; <I>See</I> 8 <I>Del. C.</I> &sect; 220(b) (emphasis added). Caligan
is a record holder of Company Common Stock and therefore did not need to accompany its Original Demand with proof of stock ownership.
Second, as a record stockholder, Caligan&rsquo;s status as a stockholder was easily verifiable by the Company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">By letter dated March 15, 2023, an affiliate of Caligan delivered a notice
of nomination to the Company, informing it of its intention to nominate the Caligan Nominees for election to the Board.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">On March 29, 2023, Caligan&rsquo;s legal counsel served a supplemental
demand upon the Company pursuant to Section 220 (the &ldquo;Supplemental Records Demand&rdquo;), noting, among other things, and in addition
to the issues raised in the Original Demand, Caligan&rsquo;s desire to investigate potential mismanagement and breaches of fiduciary duty
by members of the Company&rsquo;s management and Board that may have led up to the Company&rsquo;s poor stock performance, repeated failures
to meet revenue guidance and what Caligan believes to be excessive executive compensation schemes to date, especially since undertaking
a bet-the-company strategy of growing its joint preservation business by purchasing ArthroSurface and Parcus Medical in early 2020. In
addition, Caligan noted the Company&rsquo;s failures to disclose Mr. Darling&rsquo;s previous ties to ArthroSurface leading up to that
acquisition.</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Also on March 29, 2023, pursuant to Section 220, Caligan&rsquo;s legal
counsel delivered a routine demand letter to the Company, demanding to inspect a list of the Company&rsquo;s stockholders and related
documents (the &ldquo;Stockholder List Demand&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">On March 30, 2023, Caligan filed its preliminary proxy statement with
the SEC.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">On April 5, 2023, the Company&rsquo;s outside counsel responded to the Stockholder
List Demand by refusing to produce the requested documentation for reasons that are incorrect and inapplicable to a routine demand letter
for stockholder lists made pursuant to Section 220. On the same day, the Company&rsquo;s outside counsel also responded to the Supplemental
Records Demand by, yet again, refusing to produce a single document.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Arial, Helvetica, Sans-Serif">On April 6, 2023, Caligan&rsquo;s legal counsel delivered to the Company
an update to the Stockholder List Demand in the spirit of cooperation and expediency, even though such update was not required or necessary
under the DGCL, and reminded the Company of its obligation to provide such materials promptly under Delaware law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Also on April 6, 2023, Caligan filed this revised Proxy Statement with
the SEC.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>PROPOSAL 1: ELECTION OF DIRECTORS </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to public information, the Board currently consists of seven directors
divided into three classes in accordance with a &ldquo;classified&rdquo; structure pursuant to Article VI, Section C of the Charter. We
are soliciting proxies to elect the two Caligan Nominees as &ldquo;Class III&rdquo; directors, who, if elected, would only constitute
a minority of the Board. Even if all of the Caligan Nominees are elected, because the Caligan Nominees would only represent a minority
of the members of the Board, there can be no assurance that they would be able to implement the actions that they believe are necessary
to enhance stockholder value without the support of the other members of the Board.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">If we are successful in our proxy solicitation, the Board will be composed
of the two Caligan Nominees &mdash; Gary Peter Fischetti and James T. Hogan &mdash; and current directors Sheryl L. Conley, Stephen O.
Richard, Jeffery S. Thompson, Cheryl R. Blanchard and Glenn R. Larsen, each of whom is not up for election at the Annual Meeting. If elected,
each of the Caligan Nominees will serve a three-year term until the 2026 annual meeting of stockholders and until their successors have
been duly elected and qualified. There is no assurance that any incumbent Class III director will serve as a director if one or more of
the Caligan Nominees are elected to the Board.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Each of the Caligan Nominees has agreed to being named as a nominee in this
Proxy Statement and has confirmed his willingness to serve on the Board if elected. The age and other information related to the Caligan
Nominees shown below are as of the date of the filing of this Proxy Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">You should refer to the Company&rsquo;s Proxy Statement for the names, background, qualifications and other information concerning the
Company&rsquo;s director nominees. The Company&rsquo;s Proxy Statement and form of proxy distributed by the Company are available free
of charge on the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>Caligan Nominees:</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 1pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="3" STYLE="padding-right: 1.75pt; padding-bottom: 3pt; padding-left: 1.75pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt; text-transform: uppercase; color: #17365D"><B>GARY PETER FISCHETTI</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Age;&nbsp;&nbsp;Address</I></FONT></TD>
    <TD STYLE="width: 1%; border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="width: 82%; border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">61; 3702 Captains Way, Jupiter, Florida 33477</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Occupation</I></FONT></TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt">Corporate Director</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt">Former Medical Devices Company Group Chairman &ndash; North America
    of Johnson &amp; Johnson</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Experience</I></FONT></TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Gary Fischetti&rsquo;s principal occupation is serving as a corporate director.
    Since 2022, he has served as a member of the board of directors, and as a member of the Audit Committee, of ConforMIS, Inc. (NASDAQ: CFMS),
    a medical device company specializing in knee and hip replacements. He has also served as Chairman of the board of directors of Orchid
    Orthopedic Solutions, a world-leading provider of medical device contracting, design, and manufacturing, since 2019, and as a member of
    the board of directors of Extremity Medical, a global medical engineering company that develops next-generation products for fusion, fixation
    and motion preserving systems for the upper and lower extremities, since 2019. Mr. Fischetti has also served as a member of the board
    of directors of Acuitive Technologies, Inc. since 2023.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">From 2016 until 2018, Mr. Fischetti served as Company Group Chairman &ndash;
    North America for all Johnson &amp; Johnson&rsquo;s Medical Device businesses. Previous to this, he also served at Johnson &amp; Johnson
    as Worldwide Company Group Chairman &ndash; DePuySynthes NA from 2014 to 2015, as Worldwide Company Group Chairman &ndash; DePuy/Synthes
    Companies from 2012 to 2014 and as Worldwide President of DePuy Spine from 2005 to 2009. Through Mr. Fischetti&rsquo;s various leadership
    positions at Johnson &amp; Johnson, he oversaw the Joint Reconstruction, Spine, Trauma, CMF, and Powertools businesses, all of the DePuy
    Orthopaedic businesses, the Codman franchise and the DePuy Spine business.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt">Mr. Fischetti received a B.S.B.A. degree in finance from Villanova
    University and an M.B.A. with a concentration in Marketing from Rutgers University.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Skills &amp; Qualifications</I></FONT></TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt">Mr. Fischetti&rsquo;s qualifications as a director include his extensive
    medical device industry experience, his experience enhancing value as an executive and his service on the board of directors of numerous
    companies.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt">&nbsp;</P>
    <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="3" STYLE="padding-right: 1.75pt; padding-bottom: 3pt; padding-left: 1.75pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11pt; text-transform: uppercase; color: #17365D"><B>JAMES T. HOGAN</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Age;&nbsp;&nbsp;Address</I></FONT></TD>
    <TD STYLE="width: 1%; border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="width: 82%; border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">66; c/o Hogan Development Consulting LLC, 2808 Lucky John Drive, Park City, UT 84060</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Occupation</I></FONT></TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt"><FONT STYLE="background-color: white">Corporate Director and Consultant</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 7pt"><FONT STYLE="background-color: white">Former President of Medronic
    Latin America</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Experience</I></FONT></TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="border-bottom: #BFBFBF 1pt solid; padding-right: 1.75pt; padding-left: 1.75pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.6pt 0 7pt">James Hogan&rsquo;s principal occupation is serving as a corporate
    director and consultant. He has served as a member of the board of directors and member of the Compensation and Talent Committee and Operating
    Committee since 2020, and as a member of the Audit Committee since 2021, of Merit Medical Systems, Inc. (NASDAQ: MMSI), a manufacturer
    and marketer of proprietary disposable medical devices. Since 2019, he has served as a member of the board of directors of IONIQ Sciences,
    Inc. (formerly known as ProLung, Inc.), a company specializing in early-stage cancer detection technologies, and since 2018, as a member
    of the board of directors of Xenocor, Inc., a surgical equipment company specializing in minimally invasive imaging devices.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.6pt 0 7pt">From 2008 until 2016, Mr. Hogan served as President of Medtronic
    Latin America, the Latin American branch of Medtronic Plc, a $30 billion per year global medical technology company. He also served as
    a member of the Medtronic Senior Executive Committee and Corporate Officer groups. In 2005, Mr. Hogan joined Medtronic to lead the Gastroenterology
    and Urology Division for Western Europe, at the Medtronic International Headquarters in Tolochenaz, Switzerland. He held that position
    until 2007, during which he successfully turned around non-performing business units across Europe and Latin America, exponentially increasing
    revenues.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.6pt 0 7pt">Prior to his work with Medtronic, Mr. Hogan held numerous senior
    executive roles in other companies, including Pfizer, Inc., Coretrak SA, Argomed, Inc., and BioStent, Inc.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.6pt 0 7pt">Mr. Hogan received a B.S. in Chemistry and Psychology in 1979
    and an M.B.A. in 1981, both from the University of Minnesota.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><I>Skills &amp; Qualifications</I></FONT></TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Mr. Hogan&rsquo;s qualifications as a director include his four decades of experience driving market penetration strategies and developing sustainable business growth for best-in-class, international, multi-billion dollar companies specializing in medical devices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 11.5pt">We urge stockholders to vote <B><U>FOR</U></B> both of the Caligan Nominees on the <B><U>BLUE</U></B> proxy card.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">None of the organizations or corporations referenced above is a parent,
subsidiary or other affiliate of the Company. We believe that, if elected, each of the Caligan Nominees will be considered an independent
director of the Company under (i) the Company&rsquo;s Revised Corporate Governance Guidelines, effective December 20, 2017; (ii)&nbsp;Rule
5605(a) of NASDAQ&rsquo;s Listing Rules (the &ldquo;NASDAQ Listing Rules&rdquo;); and (iii)&nbsp;paragraph (a)(1) of Item 407 of Regulation
S-K. Under the NASDAQ Listing Rules, however, a final determination as to the independence of the Caligan Nominees will not be made until
after their election and appointment to the Board.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 3pt">Each of the Caligan Nominees has entered into a nominee agreement
(a &ldquo;Nominee Agreement&rdquo;) pursuant to which Caligan has agreed to pay the costs of soliciting proxies in connection with this
Proxy Solicitation and to defend and indemnify the Caligan Nominees against, and with respect to, any losses that may be incurred by them
in the event they become a party to litigation based on their nomination as candidates for election to the Board and the solicitation
of proxies in support of their election. Pursuant to the nominee agreements, (i) Caligan agreed to pay each Caligan Nominee $100,000 in
consideration for serving as nominee for election as director at the Annual Meeting, and (ii) each Caligan Nominee agreed to, following
the submission of a notice of nomination for his election to the Board at the Annual Meeting by an affiliate of Caligan, invest the after-tax
proceeds of such consideration in the purchase of shares of Common Stock. The Caligan Nominees will not receive any compensation from
Caligan or its affiliates for their services as directors of the Company. If elected, the Caligan Nominees will be entitled to such compensation
from the Company as is consistent with the Company&rsquo;s practices for services of non-employee directors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 3pt"><FONT STYLE="background-color: white">Each of the Caligan
Nominees has agreed to being named as a nominee in this Proxy Statement and has confirmed his willingness to serve on the Board if
elected. Caligan does not expect that any of the Caligan Nominees will be unable to stand for election, but in the event that a
Caligan Nominee is unable to or for good cause will not serve, the shares of Common Stock represented by the&nbsp;<B><U>BLUE</U></B>
proxy card will be voted for a substitute candidate selected by Caligan.&nbsp;If </FONT>Caligan determines to add or substitute
nominees, we will file an amended proxy statement and  proxy card that, as applicable, identifies the additional or
substitute nominee or nominees, discloses that such nominee or nominees have consented to being named in the revised proxy statement
and to serve if elected and includes biographical and other information about such nominee or nominees as required by the rules of
the SEC.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 3pt"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 3pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 3pt"><B><I>The Opposed Company Nominees.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9pt 0 3pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We
recommend that shareholders vote in favor of the Caligan Nominees and NOT in favor of the Opposed Company Nominees and therefore <B>&ldquo;WITHHOLD&rdquo;
</B>on such persons.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0"><FONT STYLE="background-color: white">Since Ms. Vogt joined the board
in October 2018, Anika&rsquo;s annual average TSR has underperformed the XBI by 17% annually and shareholders have lost 42% of their
investment under her tenure on the Board.<SUP>13</SUP> In Caligan&rsquo;s conversations with Ms. Vogt, she has expressed a belief that
revenue growth will drive Anika&rsquo;s valuation, without any regard for profitability or return on capital. We believe Ms. Vogt lacks
an adequate understanding of the multitude of other variables that drive shareholder returns besides revenue growth and that she has
not shown appropriate accountability for the substantial value destruction that has occurred under her tenure.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0pt"><FONT STYLE="background-color: white">Since Mr.
Henneman joined the Board on September 3, 2020, Anika&rsquo;s annual average TSR has underperformed the XBI by 15% annually and shareholders
have lost 40% of their investment under his tenure on the Board. We also have concerns regarding the independence of Mr. Henneman. He
and Dr. Blanchard overlapped on the SeaSpine (NASDAQ: SPNE) board from July 2015 through June 2019, and Mr. Henneman joined the Anika
board on September 3, 2020, within six months of Dr. Blanchard becoming CEO. Mr. Henneman has served as chairman of the compensation
committee, which has, in Caligan&rsquo;s opinion, consistently overpaid Anika management for Anika&rsquo;s terrible absolute and relative
performance and is thus primarily responsible for what Caligan believes is a misalignment of executive compensation and shareholder returns.<FONT STYLE="font-size: 8pt"><SUP>14</SUP></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0 0 0pt; font: 9pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt"><B><I>Vote Required.</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-size: 10pt">According to the Bylaws of the Company,
as a</FONT>mended (the &ldquo;<U>Bylaws</U>&rdquo;) and the Company&rsquo;s Proxy Statement, in contested elections such as this,
directors shall be elected by a plurality of the votes cast (meaning that the two director nominees who receive the highest number
of shares voted &ldquo;FOR&rdquo; their election by the common stockholders will be elected to the Board). Shares voting
&ldquo;WITHHOLD&rdquo; have no effect on the outcome of Proposal 1. Broker non-votes will not be treated as votes
cast (and therefore will have no effect on Proposal 1).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>We urge you to sign and return our <U>BLUE</U> proxy card. If you
have already voted using the Company&rsquo;s white proxy card, you have every right to change your vote by completing and mailing
the enclosed <U>BLUE</U> proxy card in the enclosed pre-paid envelope or by voting via Internet or by telephone by following the
instructions on the <U>BLUE</U> proxy card. Only the latest validly executed proxy that you submit will be counted; any proxy may be
revoked at any time prior to its exercise at the Annual Meeting by following the instructions under &ldquo;Can I change my vote or
revoke my proxy?&rdquo; If you have any questions or require any assistance with voting your shares, please contact our proxy
solicitor, D.F. King, toll free at (800) 431-9643 or collect at   (212) 269-5550.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: #365F91; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;We Urge You to vote &ldquo;FOR&rdquo; all of the
    Caligan Nominees on the <U>BLUE</U> proxy card.</B></P>
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0 0 1pt"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0"><FONT STYLE="font-size: 9pt">_______________________________________</FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0"><FONT STYLE="font-size: 9pt"><SUP>13</SUP> Through August 15,
2022, the day on which Caligan began accumulating shares of Anika.</FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0"><FONT STYLE="font-size: 9pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0"><FONT STYLE="font-size: 9pt"><SUP>14</SUP> See figures disclosed on page 63 of the Company&rsquo;s Proxy Statement.
Caligan believes Anika&rsquo;s Chief Executive Officer is overpaid because, during the last three years, she has received total aggregate
compensation of $20.1 million while the value of a $100 investment in the Company has declined to $57 (a negative 43% return) at the same
time that an equal investment in the NASDAQ Biotechnology index would have increased from $100 to $111 (a positive 11% return). Meanwhile,
the Company&rsquo;s net income has declined from $27 million in 2019 to negative $15 million in 2022.</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITOR FOR 2023</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the Board has determined
that it is desirable to request the approval of the appointment of its independent registered public accounting firm by the stockholders
of the Company. The Company&rsquo;s Proxy Statement indicates that the Audit Committee of the Board has approved the retention of <FONT STYLE="background-color: white">Deloitte
&amp; Touche LLP (&ldquo;Deloitte&rdquo;)</FONT> as the Company&rsquo;s independent auditor with respect to its consolidated financial
statements and the effectiveness of its internal control over financial reporting for the year ending, December 31, 2023. According to
the Company&rsquo;s Proxy Statement, Deloitte has served as the Company&rsquo;s independent auditor since 2017.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The Company&rsquo;s Proxy Statement states that if stockholders do not ratify
the appointment, the Audit Committee will reconsider the appointment of Deloitte. Even if the appointment is ratified, the ratification
is not binding and the Audit Committee may in its discretion select a different independent auditor at any time during the year if it
determines that such a change would be in the best interests of the Company and stockholders.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We recommend a vote <B>&ldquo;FOR&rdquo;</B> Proposal 2 on the <B><U>BLUE</U></B>
proxy card.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I>Vote Required.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the approval of Proposal
2 requires the affirmative vote of a majority of shares of Common Stock that are voting on the matter. Abstentions will not count as votes
cast and will have no effect on the vote for Proposal 2. Broker non-votes, if any, will not count as votes cast and will have no effect
on the vote for Proposal 2.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: #365F91; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;We Recommend a Vote &ldquo;FOR&rdquo; Proposal 2
    on the <U>BLUE</U> proxy card.</B></P>
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0 0 1pt"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>PROPOSAL 3: ADVISORY &ldquo;SAY-ON-PAY&rdquo; VOTE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the Company will provide
stockholders with the opportunity to vote on a non-binding advisory resolution to approve the compensation of the Company&rsquo;s Named
Executive Officers (&ldquo;NEOs&rdquo;) for the year ended December 31, 2022. The Company&rsquo;s Proxy Statement states that the Company&rsquo;s
current policy is to provide stockholders with an opportunity to vote on the compensation of its NEOs each year at its annual meeting
of stockholders. While this vote is advisory in nature, the Company&rsquo;s Proxy Statement states that the Board and the Company&rsquo;s
Compensation Committee &ldquo;<FONT STYLE="background-color: white">value the opinions of [their] stockholders and, to the extent there
is any significant vote against the NEO compensation as disclosed in [the Company&rsquo;s] Proxy Statement, [they] will consider [the]
stockholders&rsquo; concerns and the Compensation Committee will evaluate whether any actions are necessary to address those concerns.</FONT><FONT STYLE="color: #0F243E">&rdquo;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the Company will request
a non-binding, advisory vote on a resolution substantially in the following form:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><FONT STYLE="background-color: white">RESOLVED:
That the stockholders of Anika Therapeutics, Inc. approve, on an advisory basis, the compensation paid to the named executive officers
of Anika Therapeutics, Inc. as disclosed pursuant to Item 402 of Regulation S-K under the Securities Exchange Act of 1934, including the
Compensation Discussion and Analysis, compensation tables, and narrative discussion set forth in the Proxy Statement for the 2023 Annual
Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We recommend that you vote <B>&ldquo;AGAINST&rdquo;</B> Proposal 3 on the
<B><U>BLUE</U></B> proxy card because Caligan believes Anika&rsquo;s current executive compensation program does not encourage capital
discipline and does not reflect a pay-for-performance culture.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Despite the fact that the Company has had to cut its revenue forecasts
each year from 2020 through 2022, Anika&rsquo;s net income has declined from $27MM in 2019 to negative $15MM in 2022, Anika has paid
out bonuses to their named executive officers (&ldquo;NEOs&rdquo;) at 100% of target in each of 2020, 2021, and 2022.&nbsp; The
Company&rsquo;s Compensation Committee claims that it considers both &ldquo;financial performance&rdquo; and &ldquo;contribution to
increasing stockholder value&rdquo; in its assessments but seemingly ignores that the Company&rsquo;s stock has fallen by 43% and
the Company&rsquo;s net income is negative when granting annual bonuses.&nbsp; Additionally, despite the fact that net income has
significantly declined since 2019, and shareholders have lost 43% of their value from December 2019 to December 2022, the Compensation
Committee <I>increased</I> the CEO&rsquo;s annual equity grants by 56% in 2022. &nbsp;In other words, <B><U>shareholders have paid
Dr. Blanchard $20.1MM in compensation to lose 43% of their value from December 2019 through December 2022.</U></B>&nbsp; Moreover,
the Company eliminated its performance restricted units as part of the compensation package for NEOs after missing all its
performance criteria in 2020; Caligan believes this reflects a pattern whereby, instead of holding management accountable for
missing expectations, the Board just rewards NEOs regardless of performance.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We encourage all stockholders to review the Company&rsquo;s proxy disclosures
in the Company&rsquo;s Proxy Statement in detail.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the stockholder vote on
this Proposal 3 will not be binding on the Company or the Board, and it will not be construed as overruling any decision by the Company
or the Board, or creating or implying any change to, or additional fiduciary duties for, the Company or the Board.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I>Vote Required.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the approval of Proposal
3 requires the affirmative vote of a majority of the shares of Common Stock that are voting on the matter. Abstentions and broker non-votes
will not be treated as votes cast and will have no impact on Proposal 3.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: #365F91; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;We Recommend a Vote &ldquo;AGAINST&rdquo; Proposal 3 on the
<U>BLUE</U> proxy card.</B></P>
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0 0 1pt"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0; color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>PROPOSAL 4: ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the Company will, in accordance
with Section14A(a)(2) of the Exchange Act, provide stockholders with the opportunity to vote on a non-binding advisory resolution to indicate
how frequently stockholders believe the Company should seek an advisory &ldquo;say-on-pay&rdquo; vote regarding the Company&rsquo;s executive
compensation. Under Section 14A(a)(2) of the Exchange Act, generally, each public company must submit this proposal to its stockholders
not less than every six years, and this proposal was last submitted to the Company&rsquo;s stockholders at the 2017 Annual Meeting of
Stockholders. Stockholders may choose to recommend that future &ldquo;say-on-pay&rdquo; proposals be held (i) every year (&ldquo;ONE YEAR&rdquo;
on the proxy card), (ii) every two years (&ldquo;TWO YEARS&rdquo; on the proxy card) or (iii) every three years (&ldquo;THREE YEARS&rdquo;
on the proxy card). In addition, stockholders may choose to abstain from voting on Proposal 4. While this vote is advisory in nature,
the Company&rsquo;s Proxy Statement states that the Board and the Company&rsquo;s Compensation Committee &ldquo;value the opinions of
[their] stockholders and intend to take into account the outcome of the vote when considering the frequency of holding future advisory
votes on executive compensation.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We recommend a vote of <B>&ldquo;ONE YEAR&rdquo;</B> with respect to Proposal
4 on the <B><U>BLUE</U></B> proxy card.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B><I>Vote Required.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">According to the Company&rsquo;s Proxy Statement, the approval of Proposal
4 requires the affirmative vote of the holders of a majority of the shares of Common Stock present or represented at the Annual Meeting
and voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on Proposal 4.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: #365F91; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 3pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;We Recommend a Vote of &ldquo;ONE YEAR&rdquo; With
    Respect to Proposal 4 on the <U>BLUE</U> proxy card.</B></P></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE ANNUAL MEETING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>Who is entitled to vote?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Only holders of Common Stock at the close of business on the Record Date,
[ ], 2023, are entitled to notice of and to vote at the Annual Meeting. Stockholders who sell shares of Common Stock before the Record
Date (or acquire them without voting rights after the Record Date) may not vote such shares of Common Stock.&nbsp;&nbsp;Stockholders of
record on the Record Date will retain their voting rights in connection with the Annual Meeting even if they sell such shares of Common
Stock after the Record Date (unless they also transfer their voting rights).&nbsp;&nbsp;According to the Company&rsquo;s Proxy Statement,
the only outstanding class of securities of the Company entitled to vote at the Annual Meeting is the Common Stock.</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>How do I vote my shares?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Shares held in record name.</B> If your shares of Common Stock are registered
in your own name, please vote today by signing, dating and returning the enclosed <B><U>BLUE</U></B> proxy card in the postage-paid envelope
provided. Execution and delivery of a proxy by a record holder of shares of Common Stock will be presumed to be a proxy with respect to
all shares held by such record holder unless the proxy specifies otherwise.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Shares beneficially owned or held in &ldquo;street&rdquo; name.</B>
If you hold your shares of Common Stock in &ldquo;street&rdquo; name with a broker, bank, dealer, trust company or other nominee,
only that nominee can exercise the right to vote with respect to the shares of Common Stock that you beneficially own through such
nominee and only upon receipt of your specific instructions. <U>Accordingly, it is critical that you promptly give instructions to
your broker, bank, dealer, trust company or other nominee to vote in favor of the election of the Caligan Nominees</U>. Please
follow the instructions to vote provided on the enclosed <B><U>BLUE</U></B> proxy card. If your broker, bank, dealer, trust company
or other nominee provides for proxy instructions to be delivered to them by telephone or Internet, instructions will be included on
the enclosed <B><U>BLUE</U></B> proxy card. We urge you to confirm in writing your instructions to the person responsible for your
account and provide a copy of those instructions by emailing them to ANIK@dfking.com or mailing them to Caligan Partners, LP, c/o D.F.
King, 48 Wall Street, 22nd Floor, New York, New York 10005, so that we will be aware of all instructions given and can attempt to
ensure that such instructions are followed.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0; color: #231F20"><B>NOTE: IF THIS PROXY CARD IS SIGNED AND RETURNED, IT
WILL BE VOTED IN ACCORDANCE WITH YOUR INSTRUCTIONS AND AS DETAILED BELOW AS APPLICABLE. </B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 27pt; color: #231F20"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="color: #231F20"><B>1.</B></FONT></TD><TD><FONT STYLE="color: #231F20"><B>IF YOU DO NOT MARK A VOTE ON ANY OF THE PROPOSALS ON THE <U>BLUE</U> PROXY CARD, THE NAMED
                                                                                                           PROXIES (LISTED ON THE <U>BLUE</U> PROXY CARD) WILL EXERCISE THEIR DISCRETION TO CAUSE YOUR PROXY TO BE VOTED &ldquo;FOR&rdquo; THE
                                                                                                           CALIGAN NOMINEES AND TO &ldquo;WITHHOLD&rdquo; ON THE OPPOSED COMPANY NOMINEES AND</B></FONT><B> THEY WILL EXERCISE THEIR DISCRETION
                                                                                                           TO CAUSE YOUR PROXY TO BE VOTED &ldquo;FOR&rdquo; PROPOSAL 2, &ldquo;AGAINST&rdquo; PROPOSAL 3 AND &ldquo;ONE
YEAR&rdquo; WITH RESPECT TO PROPOSAL 4. THE NAMED PROXIES WILL ALSO EXERCISE THEIR DISCRETION ON ANY
                                                                                                           OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE 2023 ANNUAL MEETING. </B></TD></TR></TABLE>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; color: #231F20"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD><B>YOU MAY VOTE &ldquo;FOR&rdquo; UP TO TWO NOMINEES IN TOTAL:</B></TD></TR></TABLE>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; color: #231F20"><B>IF YOU VOTE ON AT LEAST ONE NOMINEE BUT FEWER
THAN TWO NOMINEES IN PROPOSAL 1, YOUR SHARES WILL ONLY BE VOTED &ldquo;FOR&rdquo; THOSE NOMINEES YOU HAVE SO MARKED. </B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; color: #231F20"><FONT STYLE="font-size: 8.5pt"><B>IF YOU VOTE
FOR FEWER THAN TWO NOMINEES ON YOUR <U>BLUE</U> PROXY CARD, YOUR SHARES WILL BE VOTED ONLY &ldquo;FOR&rdquo; THE NOMINEE YOU HAVE MARKED.
IF YOU VOTE &ldquo;FOR&rdquo; MORE THAN TWO NOMINEES ON YOUR <U>BLUE</U> PROXY CARD, YOUR VOTES WILL BE INVALID AND WILL NOT BE COUNTED</B></FONT><B><FONT STYLE="font-size: 7.5pt">.</FONT></B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; color: #231F20"><B><FONT STYLE="font-size: 7.5pt"></FONT></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>How should I vote on each proposal?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">Caligan recommends that you vote your shares on the <B><U>BLUE</U></B>
proxy card as follows:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in"><B>&ldquo;FOR&rdquo;</B> all of the Caligan Nominees
standing for election to the Board named in this Proxy Statement (Proposal 1);</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in"><B>&ldquo;FOR&rdquo;</B> the ratification of the Company&rsquo;s
independent auditor for 2023 (Proposal 2);</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in"><B>&ldquo;AGAINST&rdquo;  </B>the
advisory proposal to approve the compensation of the Company&rsquo;s executive officers (Proposal 3); and</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in"><B>&ldquo;ONE YEAR&rdquo;</B> on the frequency of future
advisory votes on executive compensation (Proposal 4).</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>How many shares must be present to hold
the Annual Meeting?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Under the Bylaws, <FONT STYLE="background-color: white">the holders of a
majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum
for the transaction of business at the Annual Meeting. According to</FONT> the Company&rsquo;s Proxy Statement, <FONT STYLE="background-color: white">abstentions
and broker non-votes will be counted for purposes of determining whether a quorum is present. </FONT>For more information on broker non-votes,
see &ldquo;<I>What are &ldquo;broker non-votes&rdquo; and what effect do they have on the proposals?</I>&rdquo; below.</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>What vote is needed to approve each proposal?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Proposal 1 &ndash; Election of Directors. </B>According to the
                                                                                                             Charter and Bylaws, in contested elections such as this one, directors shall be elected by a plurality of the votes cast (meaning
                                                                                                             that the two director nominees who receive the highest number of shares voted &ldquo;FOR&rdquo; their election by the stockholders
                                                                                                             will be elected to the Board). According to the Company&rsquo;s Proxy Statement, shares voting &ldquo;WITHHOLD&rdquo; and broker non-votes will not be treated as votes cast and will have no effect on Proposal 1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 6pt 0.5in; background-color: white"><B>PLEASE SUPPORT THE CALIGAN
NOMINEES BY SUBMITTING YOUR VOTING INSTRUCTIONS &ldquo;FOR&rdquo; ALL OF THE CALIGAN NOMINEES AND TO &ldquo;WITHHOLD&rdquo; ON THE
OPPOSED COMPANY NOMINEES ON THE <U>BLUE</U> PROXY CARD. PLEASE DO NOT SIGN OR RETURN A WHITE PROXY CARD FROM THE COMPANY, EVEN IF
YOU INSTRUCT TO &ldquo;WITHHOLD&rdquo; ON THEIR DIRECTOR NOMINEES. DOING SO WILL REVOKE ANY PREVIOUS VOTING INSTRUCTIONS YOU PROVIDED
ON THE <U>BLUE</U> PROXY CARD.</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 5pt; margin-bottom: 5pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Proposals 2 through 4.</B> According to the Company&rsquo;s Proxy Statement,
the approval of each of Proposals 2 through 4 requires the affirmative vote of the holders of the shares of Common Stock present or represented
at the Annual Meeting and voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact
on Proposals 2 through 4.</FONT></TD></TR></TABLE>

<P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>What are &ldquo;broker non-votes&rdquo;
and what effect do they have on the proposals?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Generally, broker non-votes occur when shares held by a broker bank, or
other nominee in &ldquo;street name&rdquo; for a beneficial owner are not voted with respect to a particular proposal because the broker,
bank or other nominee has not received voting instructions from the beneficial owner and lacks discretionary voting power to vote those
shares with respect to that particular proposal. If your shares are held in the name of a brokerage firm, and the brokerage firm has not
received voting instructions from the beneficial owner of the shares with respect to that proposal, the brokerage firm cannot vote the
shares on that proposal unless it is a &ldquo;routine&rdquo; matter. Under the rules and interpretations of the New York Stock Exchange,
there are no &ldquo;routine&rdquo; proposals in a contested proxy solicitation. Because Caligan has initiated a contested proxy solicitation,
there will be no &ldquo;routine&rdquo; matters at the Annual Meeting.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Broker non-votes, if any, with respect to the proposals set forth in this
Proxy Statement will not count as votes cast, present and entitled to vote and therefore will not be counted in determining the outcome
of any of Proposals 1, 2, 3, and 4.</P>

<P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>What should I do if I receive a proxy card
from the Company?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">You may receive proxy solicitation materials from Anika, including an opposition
proxy statement and white proxy card. We are not responsible for the accuracy of any information contained in any proxy solicitation materials
used by the Company or any other statements that it may otherwise make.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>We recommend that you disregard any proxy card or solicitation
materials that may be sent to you by the Company. Voting &ldquo;WITHHOLD&rdquo; for any of the Company&rsquo;s nominees on its proxy
card (or abstaining from voting) is not the same as voting &ldquo;FOR&rdquo; <FONT STYLE="background-color: white">the </FONT>Caligan
Nominees because a vote withheld or abstained for any of the Company&rsquo;s nominees will not count as a vote &ldquo;FOR&rdquo; the
Caligan Nominees</B>. <B>If you have already voted using the Company&rsquo;s white proxy card, you have every right to change your
vote by completing and mailing the enclosed <U>BLUE</U> proxy card in the enclosed pre-paid envelope or by voting via Internet or by
telephone by following the instructions on the <U>BLUE</U> proxy card. Only the latest validly executed proxy that you submit will
be counted; any proxy may be revoked at any time prior to its exercise at the Annual Meeting by following the instructions below
under &ldquo;Can I change my vote or revoke my proxy?&rdquo; If you have any questions or require any assistance with voting your
shares, please contact our proxy solicitor, D.F. King, toll free at (800) 431-9643 or collect at (212) 269-5550.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>Can I change my vote or revoke my proxy?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt">If you are the stockholder of record, you may change your proxy instructions
or revoke your proxy at any time before your proxy is voted at the Annual Meeting. Proxies may be revoked by any of the following actions:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">returning
                                            a later-dated proxy, either by voting by telephone or Internet, by following the instructions
                                            on the enclosed <B><U>BLUE</U> </B>proxy card from Caligan or by signing, dating and returning
                                            the enclosed <B><U>BLUE</U></B> proxy card from Caligan in the postage-paid envelope provided
                                            (the latest dated proxy is the only one that counts);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">delivering a written revocation or a later dated proxy for the Annual Meeting
to Caligan Partners LP, c/o D.F. King, 48 Wall Street, 22nd Floor, New York, New York 10005 or to the secretary of the Company; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">attending the Annual Meeting and voting in person (although attendance at
the Annual Meeting will not, by itself, revoke a proxy).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">If your shares are held in a brokerage account by a broker, bank or other
nominee, you should follow the instructions provided by your broker, bank or other nominee. If you attend the Annual Meeting and you beneficially
own shares of Common Stock but are not the record owner, your mere attendance at the Annual Meeting WILL NOT be sufficient to revoke your
prior given proxy card. You must have written authority from the record owner to vote your shares held in its name at the meeting. Contact
D.F. King, toll free at   (800) 431-9643 or collect at (212) 269-5550 for assistance or if you have any questions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>IF YOU HAVE ALREADY VOTED USING THE COMPANY&rsquo;S WHITE PROXY CARD,
WE URGE YOU TO REVOKE IT BY FOLLOWING THE INSTRUCTIONS ABOVE.</B> Although a revocation is effective if delivered to the Company, we request
that either the original or a copy of any revocation be mailed to Caligan Partners LP, c/o D.F. King, 48 Wall Street, 22nd Floor, New
York, New York 10005, so that we will be aware of all revocations.</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>Who is making this Proxy Solicitation and
who is paying for it? </I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">The solicitation of proxies pursuant to this proxy
solicitation is being made by Caligan and the Caligan Nominees. Proxies may be solicited by mail, facsimile, telephone, telegraph, Internet,
in person and by advertisements. Caligan will solicit proxies from individuals, brokers, banks, bank nominees and other institutional
holders. Caligan has requested banks, brokerage houses and other custodians, nominees and fiduciaries to forward all solicitation materials
to the beneficial owners of the shares of Common Stock they hold of record. Caligan will reimburse these record holders for their reasonable
out-of-pocket expenses in so doing. It is anticipated that certain regular employees of Caligan will also participate in the solicitation
of proxies in support of the Caligan Nominees. Such employees will receive no additional consideration if they assist in the solicitation
of proxies.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">Caligan has retained D.F. King to provide
solicitation and advisory services in connection with this solicitation. D.F. King will be paid a fee not to exceed $300,000 based
upon the campaign services provided. In addition, Caligan will reimburse D.F. King for its reasonable out-of-pocket expenses and
will indemnify D.F. King against certain liabilities and expenses, including certain liabilities under the federal securities laws.
D.F. King will solicit proxies from individuals, brokers, banks, bank nominees and other institutional holders. It is anticipated
that D.F. King will employ approximately 25 persons to solicit the Company&rsquo;s stockholders as part of this solicitation. D.F.
King does not believe that any of its directors, officers, employees, affiliates or controlling persons, if any, is a
&ldquo;participant&rdquo; in this proxy solicitation.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">The entire expense of soliciting proxies is being
borne by Caligan. Costs of this proxy solicitation are currently estimated to be approximately $[1,000,000]. We estimate that through the date
hereof, Caligan&rsquo;s expenses in connection with the proxy solicitation are approximately $[500,000]. If successful, Caligan may seek reimbursement
of these costs from the Company. In the event that it decides to seek reimbursement of its expenses, Caligan does not intend to submit
the matter to a vote of the Company&rsquo;s stockholders. The Board, which will consist of the two Caligan Nominees, if all are elected,
and five of the incumbent Company directors, would be required to evaluate the requested reimbursement consistent with their fiduciary
duties to the Company and its stockholders. Costs related to the solicitation of proxies include expenditures for attorneys, public relations
and other advisors, solicitors, printing, advertising, postage, transportation, litigation and other costs incidental to the solicitation.</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>What is Householding of Proxy Materials?
</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">The SEC has adopted rules that permit companies
and intermediaries (such as brokers and banks) to satisfy the delivery requirements for proxy statements and annual reports with respect
to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. Some banks
and brokers with account holders who are stockholders of the company may be householding our proxy materials.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white">A single copy of this Proxy Statement (and of the
Company&rsquo;s Proxy Statement and annual report) will be delivered to multiple stockholders sharing an address unless contrary instructions
have been received from one or more of the affected stockholders. Once you have received notice from your bank or broker that it will
be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your proxy.
If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement and annual report,
please notify your bank or broker and direct your request to the Secretary of the Company at 32 Wiggins Avenue, Bedford, Massachusetts
01730. Stockholders who currently receive multiple copies of this proxy statement at their address and would like to request householding
of their communications should contact their bank or broker.</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>Where can I find additional information
concerning Anika?</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Pursuant to Rule 14a-5(c) promulgated under the Exchange Act, we have omitted
from this proxy statement certain disclosure required by applicable law to be included in the Company&rsquo;s Proxy Statement in connection
with the Annual Meeting. Such disclosure includes information regarding securities of the Company beneficially owned by the Company&rsquo;s
directors, nominees and management; certain stockholders&rsquo; beneficial ownership of more than 5% of the Company&rsquo;s voting securities;
information concerning the Company&rsquo;s directors who are not up for election at the Annual Meeting; information concerning executive
compensation; and information concerning the procedures for submitting stockholder proposals and director nominations intended for consideration
at the 2024 annual meeting of stockholders and for consideration for inclusion in the proxy materials for that meeting. We take no responsibility
for the accuracy or completeness of information contained in the Company&rsquo;s Proxy Statement. Except as otherwise noted herein, the
information in this proxy statement concerning the Company has been taken from or is based upon documents and records on file with the
SEC and other publicly available information.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">This proxy statement and all other solicitation materials in connection
with this proxy solicitation will be available on the internet, free of charge, on the SEC&rsquo;s website at https://www.sec.gov.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0; color: white"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 1.8pt 0 0; color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #17365D">
    <TD STYLE="width: 100%; padding-right: 1.8pt; padding-left: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt; color: white"><B>CONCLUSION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0; color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We urge you to carefully consider the information contained in this Proxy
Statement and then support our efforts by signing, dating and returning the enclosed <B><U>BLUE</U></B> proxy card today.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">Thank you for your support,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 67px; width: 223px"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 2pt; text-align: center"><B>Caligan Partners LP</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 2pt; text-align: center"><B>Caligan Partners Master Fund LP</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 2pt; text-align: center"><B>David Johnson</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 2pt; text-align: center"><B>Gary Peter Fischetti</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 2pt; text-align: center"><B>James T. Hogan</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>[ ], 2023</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0 8.1pt 0 0; background-color: #00355B; color: white"><B>ANNEX I: INFORMATION
ON THE PARTICIPANTS</B></P>

<P STYLE="font: 2pt Arial, Helvetica, Sans-Serif; margin: 0 8.1pt 0 0; background-color: #00355B">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We urge you to carefully consider the information contained in this Proxy
Statement and then support our efforts by signing, dating, and returning the enclosed <B><U>BLUE</U></B> proxy card today.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">This Proxy Solicitation is being made by Caligan Partners LP (&ldquo;Caligan
Partners&rdquo;), Caligan Partners Master Fund LP (&ldquo;Caligan Fund&rdquo;) and David Johnson, a citizen of the United States (&ldquo;Mr.
Johnson,&rdquo; and, together with Caligan Partners, Caligan Fund, &ldquo;Caligan&rdquo;), and the Caligan Nominees (collectively, the
&ldquo;Particpants&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">As of the close
of business on [ ], 2023, the Participants may be deemed to beneficially own, in the aggregate, [726,161] shares of Common Stock, representing
approximately [&#9679;]% of the Company&rsquo;s outstanding shares of Common Stock. The percentages contained herein are based upon [</FONT><FONT STYLE="font-family: Wingdings">l</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">]
shares of Common Stock outstanding as of [</FONT><FONT STYLE="font-family: Wingdings">l</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">],
as reported in Company&rsquo;s Definitive Proxy Statement filed on Schedule 14A with the SEC on [ ], 2023.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">As of the close of business on [&#9679;], 2023, Caligan may be deemed to
beneficially own, in the aggregate, [720,291] shares of Common Stock. Of the [720,291] shares of Common Stock beneficially owned in the
aggregate by Caligan: (a) [231,794] shares of Common Stock are held by Caligan Fund, including 1,000 shares of Common Stock held in record
name and [488,497] shares of Common Stock held directly by certain other accounts managed by Caligan; (b) [720,291] shares of Common Stock
may be deemed to be beneficially owned by Caligan Partners by virtue of it being the investment manager of Caligan Fund and such managed
accounts; and (c) [720,291] shares of Common Stock may be deemed to be beneficially owned by Mr. Johnson, by virtue of his status as the
Managing Partner Caligan Partners and Managing Member of Caligan Partners GP, LLC, the general partner of the Investment Manager. In addition,
2,320 shares of Common Stock may be deemed to be beneficially owned by Gary Fischetti, a Nominee (&ldquo;Mr. Fischetti&rdquo;), and 3,550
shares of Common Stock may be deemed to be beneficially owned by James T. Hogan, a Nominee (&ldquo;Mr. Hogan&rdquo;).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Arial, Helvetica, Sans-Serif">Caligan and each of Messrs. Fischetti and Hogan may be deemed a &ldquo;group&rdquo;
as defined in Rule 13d-5 of the Exchange Act and pursuant to such definition, Mr. Fischetti, Mr. Hogan, and Caligan may be deemed to
collectively and beneficially own an aggregate [726,161] shares of Common Stock. Caligan disclaims beneficial ownership
over the shares that may be deemed to be beneficially owned by Mr. Fischetti and Mr. Hogan. Mr. Fischetti disclaims beneficial ownership
over the shares that may be deemed to be beneficially owned by Mr. Hogan and Caligan. Mr. Hogan disclaims beneficial ownership over any
shares that may be deemed to be beneficially owned by Mr. Fischetti and Caligan.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">The shares of Common Stock beneficially owned by Caligan
may be held in commingled margin accounts, which may extend margin credit to the funds and managed accounts advised by Caligan Partners
from time to time, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the
positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account. The margin
accounts bear interest at a rate based upon the broker&rsquo;s call rate from time to time in effect. Because other securities are held
in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the shares of Common Stock reported
herein.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">The principal address of Caligan Fund is c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand
Cayman, KY1-1104, Cayman Islands. In addition, Caligan Fund has as a business address c/o Caligan Partners LP, 515 Madison Avenue, 8<SUP>th
</SUP>Floor, New York, New York 10022. The principal address of each of Caligan Partners and Mr. Johnson is 515 Madison Avenue, 8<SUP>th
</SUP>Floor, New York, New York 10022.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The principal business of (i) Caligan Fund is to serve as
a private investment fund and (ii) each of Caligan Partners and Mr. Johnson is investment management.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Each of the Caligan
Nominees is a United States citizen. The principal business addresses, along with the principal occupation, of each of the Caligan Nominees
is disclosed in the section titled &ldquo;PROPOSAL 1: THE ELECTION OF DIRECTORS&rdquo; beginning on page [</FONT><FONT STYLE="font-family: Wingdings">l</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">].</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Except as set forth in this Proxy Statement (including this Annex),
(i) during the past ten years, no Participant has been convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors); (ii) no Participant in this Proxy Solicitation directly or indirectly beneficially owns any securities of the
Company; (iii) no Participant owns any securities of the Company which are owned of record but not beneficially; (iv) no Participant
has purchased or sold any securities of the Company during the past two years; (v) no part of the purchase price or market value of
the securities of the Company owned by any Participant is represented by funds borrowed or otherwise obtained for the purpose of
acquiring or holding such securities; (vi) no Participant is, or within the past year was, a party to any contract, arrangements or
understandings with any person with respect to any securities of the Company, including, but not limited to, joint ventures, loan or
option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits or the giving or
withholding of proxies; (vii) no associate of any Participant owns beneficially, directly or indirectly, any securities of the
Company; (viii) no Participant owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the Company;
(ix) no Participant or any of his or its associates was a party to any transaction, or series of similar transactions, since the
beginning of the Company&rsquo;s last fiscal year, or is a party to any currently proposed transaction, or series of similar
transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds
$120,000; (x) no Participant or any of his or its associates has any arrangement or understanding with any person with respect to
any future employment by the Company or its affiliates, or with respect to any future transactions to which the Company or any of
its affiliates will or may be a party; and (xi) no person, including any of the Participants, who is a party to an arrangement or
understanding pursuant to which the Caligan Nominees are proposed to be elected, has a substantial interest, direct or indirect, by
security holdings or otherwise in any matter to be acted on as set forth in this Proxy Statement. There are no material proceedings
to which any Participant or any of his or its associates is a party adverse to the Company or any of its subsidiaries or has a
material interest adverse to the Company or any of its subsidiaries. With respect to each of the Caligan Nominees, except as set
forth in this Proxy Statement (including the Annexes), none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K of the
Exchange Act occurred during the past ten years. Neither the Caligan Nominees nor any associate of a Nominee has served as a
director or named executive officer of the Company at any point during the last three fiscal years of the Company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12.5pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white"><B><I>Transactions by the Participants with respect
to the Company&rsquo;s securities</I></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: #00355B 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">The following tables set forth all transactions effected during the past
two years by the Participants with respect to securities of the Company. The shares of Common Stock reported herein are held in cash accounts
in the ordinary course of business. Unless otherwise indicated, all transactions were effected on the open market.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Caligan, by virtue of its direct and indirect control over Caligan
 Fund and managed accounts.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 16%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Date</U></B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 25%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B>Common
                                            Stock Acquired</B></FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B>(<U>Disposed</U>)</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 22%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Date</U></B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 20%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Common
                                            Stock</U></B></FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Acquired
                                            (Disposed)</U></B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/15/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">33,000</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10/7/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">27,500 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/16/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">15,379</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10/10/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">67,500 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/17/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9,610</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10/11/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">45,000 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/18/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,617</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">11/30/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9,209 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/19/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2,500</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/8/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(3,395)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/22/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">17,894</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/15/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10,000 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/23/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,000</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/19/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">20,000 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/24/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">7,365</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/21/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">100 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/26/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">6,224</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/22/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">6,007 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/29/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">13,776</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/29/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,000 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/30/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">23,628</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12/30/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">4,789 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8/31/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">11,372</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1/6/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(117)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/1/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10,000</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1/10/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(9,883)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/2/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">20,000</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1/13/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(7,573)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/6/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">25,000</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1/17/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(2,427)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/7/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">7,756</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2/14/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">6,000 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/9/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10,931</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2/21/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">20,000 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/12/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3,113</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2/28/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/15/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">7,192</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/7/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,654</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/16/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">14,128</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/10/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,675</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/19/2022</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">6,796</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/13/2023</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12,240</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/20/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3,005</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/17/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">20,000</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/23/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">31,945</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/21/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">8,579</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/26/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">16,934</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/22/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">22,660</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/27/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12,286</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/23/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9,148</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/29/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">4,714</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/24/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,547</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9/30/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">73,000</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/27/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,936</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10/3/2022</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,800 </FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/28/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">19</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"></FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/29/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">58</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/30/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">10,000</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/31/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">15,000</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">4/4/2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,000</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Mr. Fischetti</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 50; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Date</U></B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 74%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Common Stock Acquired (Disposed)</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/28/2023</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2,320</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Mr. Hogan</B><SUP></SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 50; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Date</U></B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 52%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><U>Common Stock Acquired (Disposed)</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/23/2023</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">910</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/28/2023&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,770&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">3/29/2023&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">870&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-size: 9pt"></FONT></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>IMPORTANT</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">Tell your Board what you think! YOUR VOTE IS VERY
IMPORTANT, no matter how many or how few shares you own. Please give us your proxy <B>&ldquo;FOR&rdquo; </B>all of the Caligan
Nominees by taking three steps:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify">&#9679;&#9;SIGNING the enclosed <B><U>BLUE</U></B>
proxy card,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify">&#9679;&#9;DATING the enclosed <B><U>BLUE</U></B>
proxy card, and</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify">&#9679; MAILING the enclosed <B><U>BLUE</U></B> proxy card TODAY in the envelope provided (no postage is required
if mailed in the United States).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><B>If any of your shares are held in the name of a
broker, bank, bank nominee or other institution, only it can vote your shares and only upon receipt of your specific instructions.</B>
Depending upon your broker or custodian, you may be able to vote either by toll-free telephone or by the Internet. You may also vote by
signing, dating and returning the enclosed <B><U>BLUE</U></B> voting form in the postage-paid envelope provided, and to ensure that your
shares are voted, you should also contact the person responsible for your account and give instructions for a <B><U>BLUE</U></B> proxy
card to be issued representing your shares.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">After signing the enclosed <B><U>BLUE</U></B> proxy
card, <B>DO NOT SIGN OR RETURN ANIKA&rsquo;S WHITE PROXY CARD UNLESS YOU INTEND TO CHANGE YOUR VOTE</B>, because only your latest dated
proxy card will be counted.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">If you have previously signed and returned a white
proxy card to Anika, you have every right to change your vote. Only your latest dated proxy card will count. You may revoke any proxy
card already sent to Anika by signing, dating and mailing the enclosed <B><U>BLUE</U></B> proxy card in the postage-paid envelope provided
or by voting by telephone or Internet. Any proxy may be revoked at any time prior to the 2023 Annual Meeting by delivering a written notice
of revocation or a later dated proxy for the 2023 Annual Meeting to D.F. King or by voting in person at the Annual Meeting. Attendance
at the Annual Meeting will not in and of itself constitute a revocation.</P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><I>If you have any questions concerning this proxy statement,
would like to request additional copies of this proxy statement or need help voting your shares, please contact our proxy solicitor:</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<DIV STYLE="text-align: center; padding: 1pt 1pt 6pt; border: Black 1.5pt solid">

<IMG SRC="image_007.jpg" ALT=""><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B><BR></B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>D.F. King &amp; Co., Inc.</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>48 Wall Street, 22nd Floor</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>New York, New York 10005<BR>
<BR>
</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>Banks and Brokers Call Collect: (212) 269-5550</B></P>




<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>All Others Call Toll-Free: (800) 431-9643</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>Email: ANIKA@dfking.com</B></P>

</DIV>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><SUP></SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-size: 9pt"></FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 13.5pt; text-align: center; color: #ED2A25"><B>[PRELIMINARY
COPY SUBJECT TO COMPLETION]</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>PLEASE SUBMIT
YOUR VOTE TODAY!</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>SEE REVERSE
SIDE</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.65pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 23pt; color: #231F20; text-align: center"><B>FOR THREE EASY
WAYS TO VOTE.</B></P>

<P STYLE="font: 13.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 58.25pt; color: #231F20"><FONT STYLE="font-family: Marlett">6</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">TO
VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE AND SIGN, DATE, AND RETURN IN THE POSTAGE-PAID ENVELOPE PROVIDED</FONT><FONT STYLE="font-family: Marlett">6&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Marlett; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.3in 0pt 0.25in; text-align: center"><B>ANIKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.3in 0pt 0.25in; text-align: center"><B>Proxy Card for 2023 Annual Meeting
of Stockholders</B></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.3in 0pt 0.25in; text-align: center"><B>Scheduled for [ ], 2023 (the &ldquo;Annual
Meeting&rdquo;): </B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.3in 0pt 0.25in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.3in 0pt 0.25in; text-align: center"><B>THIS PROXY SOLICITATION IS BEING
MADE BY CALIGAN PARTNERS LP AND CERTAIN OF ITS AFFILIATES (COLLECTIVELY, THE &ldquo;CALIGAN,&rdquo; &ldquo;WE&rdquo; OR &ldquo;US&rdquo;)
AND GARY PETER FISCHETTI AND JAMES T. HOGAN (THE &ldquo;CALIGAN NOMINEES&rdquo;)</B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.3in 0pt 0.25in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.45pt 0pt 28.45pt; text-align: center"><B>THE BOARD OF DIRECTORS OF
ANIKA THERAPEUTICS, INC. IS NOT SOLICITING THIS PROXY</B></P>

<P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.45pt 0pt 28.3pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>B</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>L</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>U</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>E</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="width: 94%; font-size: 12pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20">T</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">he
undersigned appoints David Johnson, Edward T. McCarthy and Eleazer Klein, and each of them, attorneys and agents with full power of substitution
to vote all shares of common stock of Anika Therapeutics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), that the undersigned
would be entitled to vote at the Annual Meeting of stockholders of the Company scheduled to be held via live audio webcast on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2023 at [&nbsp;&nbsp;&nbsp;&nbsp;] a.m. Eastern time, including at any adjournments or postponements thereof, with all powers that the
undersigned would possess if personally present, upon and in respect of the instructions indicated herein, with discretionary authority
as to any and all other matters that may properly come before the meeting or any adjournment, postponement or substitution thereof that
are unknown to Caligan a reasonable time before this solicitation.</FONT></P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&nbsp;&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>P</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>R</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>O</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>X</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>Y</B></P></TD>
    <TD>
    <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The undersigned hereby revokes any other proxy or proxies heretofore
    given to vote or act with respect to said shares, and hereby ratifies and confirms all action the herein named attorneys and proxies,
    their substitutes, or any of them may lawfully take by virtue hereof. This proxy will be valid until the sooner of one year from the date
    indicated on the reverse side and the completion of the Annual Meeting (including any adjournments or postponements thereof).</P>
    <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">None of the matters currently intended to be acted upon pursuant to this
    proxy are conditioned on the approval of other matters. No assurance can be given that the Company&rsquo;s nominees will serve if elected
    with any of the Caligan Nominees.</P>
    <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><B>IF THIS PROXY CARD IS SIGNED AND RETURNED, IT WILL
    BE VOTED IN ACCORDANCE WITH YOUR INSTRUCTIONS AND AS DETAILED BELOW AS APPLICABLE. </B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>C</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>A</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>R</B></P>
    <P STYLE="font: 15.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; color: #231F20"><B>D</B></P>
    <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 26.25pt; text-indent: -0.25in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT><FONT STYLE="font-size: 8.5pt; color: #231F20"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;IF
YOU DO NOT MARK A VOTE ON ANY OF THE PROPOSALS ON THE <U>BLUE</U> PROXY CARD, THE NAMED PROXIES (LISTED ABOVE) WILL EXERCISE THEIR DISCRETION
TO CAUSE YOUR PROXY TO BE VOTED &ldquo;FOR&rdquo; THE CALIGAN NOMINEES AND TO &ldquo;WITHHOLD&rdquo; ON THE  COMPANY&rsquo;S NOMINEES
AND</B></FONT><B> <FONT STYLE="font-size: 8.5pt">THEY WILL EXERCISE THEIR DISCRETION TO CAUSE YOUR PROXY TO BE &ldquo;FOR&rdquo; PROPOSAL
2, &ldquo;AGAINST&rdquo; PROPOSAL 3 AND FOR &ldquo;ONE YEAR&rdquo; WITH RESPECT TO PROPOSAL 4<FONT STYLE="color: #231F20">. THE NAMED
PROXIES WILL ALSO EXERCISE THEIR DISCRETION ON ANY OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE 2023 ANNUAL MEETING. </FONT></FONT></B></P>
    <P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 26.25pt; color: #231F20"><B>&nbsp;</B></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 26.25pt; text-indent: -13.5pt; color: #231F20"><FONT STYLE="font-size: 7.5pt"><B>2.&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-size: 8.5pt">YOU
    MAY VOTE &ldquo;FOR&rdquo; UP TO TWO NOMINEES IN TOTAL: IF YOU VOTE FOR FEWER THAN TWO NOMINEES ON YOUR <U>BLUE</U> PROXY CARD, YOUR
    SHARES WILL BE VOTED ONLY &ldquo;FOR&rdquo; THE NOMINEE YOU HAVE MARKED. IF YOU VOTE &ldquo;FOR&rdquo; MORE THAN TWO NOMINEES ON
    YOUR <U>BLUE</U><I>&nbsp;</I>PROXY CARD YOUR VOTES WILL BE INVALID AND WILL NOT BE COUNTED</FONT><FONT STYLE="font-size: 7.5pt">.
    </FONT></B></P></TD></TR>
  </TABLE>
<P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 19.45pt; margin-bottom: 0pt; text-align: left; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #231F20"><I>(continued and to be signed on
the reverse side)</I></P>

<P STYLE="font: 12pt/85% Arial, Helvetica, Sans-Serif; margin-top: 5.45pt; margin-bottom: 0; text-align: center; color: #ED2A25"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="vertical-align: top; width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/85% Arial, Helvetica, Sans-Serif; margin-top: 5.45pt; margin-bottom: 0; text-align: left; color: #ED2A25">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.35pt 0pt 0; text-align: center; color: #231F20"><B>YOUR VOTE IS IMPORTANT</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 90.35pt 0pt 94.5pt; text-align: center; color: #231F20">Please take a moment
now to vote your shares of ANIKA THERAPEUTICS, INC.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 81.35pt 0pt 1.5in; text-align: center; color: #231F20">Common Stock for
the upcoming Annual Meeting of Stockholders.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 19.6pt 0pt 18.2pt; text-align: center; color: #231F20"><B>YOU CAN VOTE
TODAY USING ANY OF THE FOLLOWING METHODS:</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 12pt; text-align: justify"><IMG SRC="internet.jpg" ALT=""><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: #231F20"><B><I>&nbsp;</I></B></FONT></TD>
    <TD STYLE="width: 90%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20"><B><I><U>Submit your proxy by Internet</U></I></B></P>
    <P STYLE="font: 9.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20">Please access [&#9679;] (please
    note you must type an &ldquo;s&rdquo; after &ldquo;http&rdquo;). Then, simply follow the easy instructions on the voting site. You will
    be required to provide the unique Control Number printed below.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><IMG SRC="phone.jpg" ALT=""><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: #231F20"><B><I>&nbsp;</I></B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20"><B><I><U>Submit your proxy by Telephone</U></I></B></P>
    <P STYLE="font: 9.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20">Please call toll-free in the U.S.
    or Canada at <B>[ ]</B> on a touch-tone telephone. If outside the U.S. or Canada, call <B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</B>.
    You will be required to provide the unique control number printed below.</P>
    <P STYLE="font: 9.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="width: 25%; border-right: Black 1pt solid; font-size: 12pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; color: #231F20">CONTROL NUMBER</FONT></TD>
    <TD STYLE="width: 35%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 12pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 90%; background-color: #D9D9D9; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 40.3pt 0pt 0; text-align: center; color: #231F20">You may vote by telephone
    or Internet 24 hours a day, 7 days a week.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 40.3pt 0pt 0; text-align: center; color: #231F20">Your telephone or
    Internet vote authorizes the named proxies to vote your shares in the same manner</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 40.3pt 0pt 0; text-align: center; color: #231F20">as if you had marked, signed and returned the <B><U>BLUE
    </U>proxy card from Caligan.</B></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.6pt; color: #231F20"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: #231F20"><B><I>&nbsp;<IMG SRC="mail.jpg" ALT=""></I></B></FONT></TD>
    <TD STYLE="width: 90%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><B><I><U>Submit your proxy by Mail</U></I></B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: -0.15pt"><FONT STYLE="color: #231F20">Please complete,
    sign, date and return the <B><U>BLUE</U></B> proxy card in the envelope provided to: </FONT>Caligan Partners, LP, c/o D.F. King, 48 Wall
    Street, 22nd Floor, New York, New York 10005</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.6pt; color: #231F20"><B><I></I></B></P>

<P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><FONT STYLE="font-family: Marlett">6</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">TO
VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE AND SIGN, DATE AND RETURN IN THE POSTAGE-PAID ENVELOPE PROVIDED</FONT><FONT STYLE="font-family: Marlett">6</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Marlett; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #231F20"></P>

<P STYLE="font: 1pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 5%; font-size: 12pt"><FONT STYLE="font-family: Wingdings; font-size: 16pt; color: #231F20">x</FONT></TD>
    <TD STYLE="width: 95%">
    <P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 18.35pt 0pt 0; color: #231F20"><B>Please mark vote
as in this sample</B></P></TD></TR>
  </TABLE>


<div style="float: left; width: 48%">
<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 12pt">
  <TR>
    <TD COLSPAN="6"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20"><B>Proposal 1 </B>&ndash; Election of Directors for terms ending in 2026</FONT></TD></TR>
  <TR STYLE="background-color: #D9D9D9">
    <TD COLSPAN="6"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20"><B>Caligan recommends voting &ldquo;<U>FOR</U>&rdquo; the Caligan Nominees</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 9.35pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 30%; padding-left: 0.05in">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 10%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>FOR</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 12%; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>WITHHOLD</B></FONT></TD>
    <TD STYLE="width: 23%; padding-left: 9.35pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 11%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>FOR</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>WITHHOLD</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.05in; text-indent: -0.05in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20">Gary T. Fischetti</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20">James T. Hogan</FONT></TD>
    <TD STYLE="padding-left: 30.85pt; text-align: center; text-indent: -30.85pt"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.05in; text-indent: 4.45pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 9.35pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 9.35pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #D9D9D9">
    <TD COLSPAN="6"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20"><B>Caligan Recommends to &ldquo;<U>WITHHOLD</U>&rdquo; on the Opposed Company Nominees</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-left: 8.05pt; text-indent: 4.55pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 1.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 1.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>FOR</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>WITHHOLD</B></FONT></TD>
    <TD STYLE="padding-left: 8.05pt; text-indent: 4.55pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 1.25pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>FOR</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 1.25pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>WITHHOLD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20">John B. Henneman, III</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20">Susan L. N. Vogt</FONT></TD>
    <TD STYLE="padding-left: 19.9pt; text-align: center; text-indent: -19.9pt"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center; text-indent: 0in"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD></TR>
  </TABLE>
</div>

<div style="float: right; width: 48%">


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 97%">&nbsp;</TD>
  <TD STYLE="border-top: Black 3pt solid; width: 3%; border-right: Black 3pt solid">&nbsp;</TD></TR>
</TABLE>







<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 12pt">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="background-color: #D9D9D9; text-indent: 0.35pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6.5pt; color: #231F20"><B>Caligan recommends voting &ldquo;FOR&rdquo; Proposals 2, &ldquo;AGAINST&rdquo; Proposal 3 and &ldquo;ONE YEAR&rdquo; on Proposal 4.&nbsp;&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="text-align: center; font: 6pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><B>FOR</B></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>&nbsp;AGAINST</B></FONT></TD>
    <TD STYLE="padding-left: 3pt">
    <P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.6pt 0pt 0; text-align: center; color: #231F20"><B>ABSTAIN</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20"><B>Proposal 2 </B>&ndash; R</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">atification of the appointment of Deloitte &amp; Touche, LLP as the Company&rsquo;s independent auditor for 2023</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="padding-left: 3pt; text-align: center; text-indent: 0.35pt"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center; text-indent: 0.35pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">
    <P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.6pt 0pt 0; color: #231F20"><B>FOR</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>AGAINST</B></FONT></TD>
    <TD STYLE="padding-left: 3pt; vertical-align: bottom; text-align: center; text-indent: 0.35pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="text-align: center; text-indent: 0.35pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20"><B>Proposal 3 </B>&ndash; </FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">Consideration of an advisory &ldquo;say-on-pay&rdquo; vote</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="padding-left: 3pt; text-align: center; text-indent: 0.35pt"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center; text-indent: 0.35pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 3pt; text-align: center; text-indent: 0.35pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0.35pt">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">
    <P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.6pt 0pt 0; color: #231F20"><B>ONE</B></P>
    <P STYLE="font: 6pt Arial, Helvetica, Sans-Serif; margin: 0pt 1.6pt 0pt 0; color: #231F20"><B>YEAR&nbsp;</B></P></TD>
    <TD STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>TWO</B></FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>YEARS</B></FONT></P></TD>
    <TD STYLE="padding-left: 3pt; text-align: center; text-indent: 0.35pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>THREE</B></FONT></P>
                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt; color: #231F20"><B>YEARS</B></FONT></P></TD>
    <TD STYLE="text-align: center; text-indent: 0.35pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt"><B>ABSTAIN</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20"><B>Proposal 4 </B>&ndash; Consideration of an advisory vote on the frequency of future advisory votes on executive compensation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="padding-left: 3pt; text-align: center; text-indent: 0.35pt"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    <TD STYLE="text-align: center; text-indent: 0.35pt"><FONT STYLE="font-family: Wingdings; color: #231F20">&uml;</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 7.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #221F1F"><B>PLEASE <U>SIGN</U>, <U>DATE</U> AND <U>PROMPTLY
    RETURN</U> THIS PROXY CARD USING THE ENCLOSED ENVELOPE</B></P>
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 2.95pt 0pt 0; color: #231F20">&nbsp;</P>
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 2.95pt 0pt 0; color: #231F20"><B>ONLY VALID IF SIGNED AND DATED</B>. Please
    sign EXACTLY as name appears hereon. If more than one owner, each should sign. When signing as attorney, executor, administrator, trustee
    or guardian, please give full title as such. If a corporation or partnership, please sign in full corporate or partnership name by authorized
    officer.<BR>
    <BR>
    </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 12pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 12pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">Signature [PLEASE SIGN WITHIN BOX]</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 2.95pt 0pt 0; text-align: justify; color: #231F20">&nbsp;</P>
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 2.95pt 0pt 0; text-align: justify; color: #231F20">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 12pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 12pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">Signature (if jointly held) [PLEASE SIGN WITHIN BOX]</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">Date</FONT></TD></TR>
  </TABLE>
</div>
<BR>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 3pt solid; border-left: Black 3pt solid; width: 3%">&nbsp;</TD>
  <TD STYLE="width: 97%">&nbsp;</TD></TR>
</TABLE>
<DIV STYLE="position: relative; float: left; width: 48%; padding-right: 1%">
</DIV>


<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 414.35pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U/7[O(
MQ67KWB#3?"^EW&I:O?0:=8PKNDN+N58T0>[=J\6_:,_:J\/? .R6P6/^VO%5
MQ'OATY7VK&O_ #TE;^%?]G[S?^/5^<GQ7^.7B_XS:I]K\3:I)<0JV^"QA^2W
M@_W$_P#9_O5[&!RRKB_>E[L3Q\5F%/#^['WI'UG\;_\ @H=%9R7&D?#BT6YE
M7Y6UR]CRGUBB_B_WF_[YKXO\9?$CQ/\ $"^:[\2:]J&KS[MW^E3NR)_N)]U/
M^ 5V'P:_9Q\:_&V\3^Q-/^S:4K;9-4O!Y<$?_ OXV_V4K[?^'_\ P3Z^'/A[
M2@/$27?BC4F7]Y+-,]K$K?[*1-_Z$SU]#[;!97[L/B_$\?V>+Q_O/X3XK^$_
M[5'Q!^$MU$-/UN;4M,7[VE:FS7%OL_V/XE_X#MK[V^!_[8O@WXR"#3YYE\->
M)'^3^SKV0;96_P"F4G1_]WY6]J\9^,__  3KB\F74OAS?-YJ_/\ V/J4O#>T
M<O\ \7_WU7Q3XF\)ZSX*UJ?3-<TVXTG481EK>XCVM42HX'-(\U+28HU<5ETN
M6?PG[?\ R[>.12C&VOR_^ _[<7BSX7O;Z7XC>3Q/X;7Y=LS9NH%_Z92_Q_[K
M?^.5^C'P_P#'^B_$WPQ::]H-XE]IURN5D7[RM_$K+_"PKYC%8"M@Y6G\)]!A
ML;2Q/P_$=3QZ44<>M?+OQO\ V]O _P )=7N-$T^WN/%FMVK;)XK*5(X(&_N/
M*<_-_N*U<=*E.I+EIQ.RI4C3C>1]2;:9@5\-^%?^"HF@ZAJ$<'B3P9?:+:2-
ML^U6=XEUL_WE9$K[%\'>,M&\>>'[36M!U&'5-+NEW17%N^5;I_WR?]FM*U"I
M1_B1(IUX5?@9T&1MI,C;7G7QT^,&G_ _X;ZCXLU"!KI+8I'#:(X1[B1G"JBG
M\2W^ZK5S?[-/[2>E_M'^&]5U*UTU]&O=-N5@GT^2;S6164.DN[:ORM\W_?%1
M[&;A[2WNE>TCS\G4]K]*#BFDX_*OG3X#?M<V'QV^)&M^$;;P[<Z1)IEM)</=
M2W*R*^R58MH4+ZO4QIRG%RBOA"52,91B^I]'4G%!^[7DO[1GQVM_V?/ D'B:
MZTJ?6()KZ*R-O#,L17<KMNW'_<J8QE*7+$N4HQ5Y'K/&VCC'-</\'_B+!\6O
MAKHOBV"RDTZ'5(VE2UFDWLFUV3EA_NUYQ\?/VQ/!/P%NFTR[:XUWQ#MW#2M/
MVDQ?W?-<_<!]MS?[-7&C4G/DA'WB)5(PCS2V/?Z/PKX.TO\ X*EZ9)?[=5^'
M]W:66[_76NIK+*J^NQHD_P#0J^N?A3\8/"WQG\,IKGA74EOK7.R6-AME@?\
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M7L=/-0C/3XCY3_;Q\9:E\7OC1X7^#WAY_.>UN(O/5?N?;)^$+?\ 7*)L_P#
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MI7R)SNKEPL9>W@=.)DO92.E_9]\7+\/OV'=+\2^5YSZ7HEY>K%_>=))F5?\
MOKBOFG]AOX*V'QX\9>)_B#XZ']O"TNODANQO2YNI=SN\J_Q;/[O3Y_\ 9KZ1
M^ OA(_$#]A?3O#D;K')JNAWEI&S=%=Y)57/_  *OG+]@GXT:;\&_%'BCX?\
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MY_9Q_P"2 _#C_L7K#_TG2OQ6\0Z5+H/B#4],G79+9W4MNR?[2/LK]J/V<?\
MD@7PX_[%ZP_])THSG^' O*_XDCY>_:DA9?C)JK,N4:*!E_[])7E"7,L/^JE9
M/]QJ^^_BA\%]"^*-JCWJ-::E$FR*^AX=5_NM_>6OE'QQ^SGXQ\(7WEP:9/K=
MHS?NKC3XGEW?[ZK\RU\N?0GE[NSMN9M[U]I?LBQM'\*[AF7EM1D=?^_45>;?
M#/\ 9/U#56AOO%<K:=:_?%C%_KW_ -X_PU]3:#H-AX7TF#3=,MTM+*W7;'"G
M04 <7\4/CQX&^"[::OC'6ET=M2$C6NZVEE\W9MW_ .K1O[ZU1^&O[2'P\^,.
MNRZ-X3\0KJNHQ6[7;P"UGB*Q*ZIN^=%_B=?SKX)_X*+?%C1_B!\3-(T/1[J&
M]B\.VTL5S<0G<OGRL R*W\6S8G_ MU;'_!+W3Y)?B]XFOMG[J#0VA9O]MKB+
M_P"(>O8^H1CA?K$MSR?KDIXGV4?A/TR917RC\;/^"?\ X,^*6M76M:/?3^#M
M7NF,D_V.!9K61O[YB^7:WNK"OJN7Y8F^E?,'@_Q!X\U_X?W_ (K/Q#BL_L;2
M_P"@W5E%^\V)N^__ +7^Y7DTJLZ,N:$K'IU*<:L>61YMX,_X)=Z-I^I1S^)_
M&=YJ]JC;OLNGV?V7?_O,SO7N/QB_9AT_XB_"S2OA_HFKKX*\.V<R2M;V=F)%
MEVYVJWSK_&V__::O4/AWXCF\7>"])U:XC2&XNH-\JQ_=W?=W+_L\&N)^.GB_
MQ#I-QH>@>$)O)U^^:6XSM5_W42YV?-_>_P#9:UEB:LY<TI&<<-2C&RB=%\%?
MA/IWP5^'.E>%=.E:XALU9I+J1=KSR,Q9G;W)-=)XL\,V7C3PSJNA:C$)K#4K
M:2UG0]T==IK$^$?BP^-_A_I&I2R;[IH_*N6_Z:I\K'_@7WO^!5?^(VI7.A^
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M9[G4M0N&^>:9GEEE;_V:OJKX!_\ !/;Q9\1&M]7\:M)X1T%OF6W9?^)A.O\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M7O$>W<-)T_:3%_=\US]P'VW-_LU<:,YSY(1]XB52,(\TMCZ!_"C/M7P;I?\
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M1[.W1Y?N*SW=PM=E_P $X/B9<^'_ !!XG^%&NEK6[25[RSMYOO13Q_)<1?\
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M>"_^"7NB:?J$<_BGQI>:U:(V\6ME9_9=_P#O,SN:]Q^,7[,.G?$3X6:5\/\
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M;[F\IW7;_P "V?W?XJ]R^&/B&Z\4> ]'U;4(%M[R[BW.BKM#?,5WX_VOO?\
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M_(7EE'7[I=CL_P" XKZ-HHKAQC;JSN=6#_A1'T445QG>%%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MVIM!U#P_X\\:_%6YL)?%W@WP;\2M1FUCPLR[U@1E3_B91)_%+%_=;^[_ +U
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A\3-SEW9-1116YR!1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>internet.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 internet.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>phone.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 phone.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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6@*_<B@EVZ!1110(**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>mail.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mail.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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&,XHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &1 YT# 2(  A$! Q$!_\0
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M_-_C5>B@"Q_:%]_S^W7_ '^;_&C^T+[_ )_;K_O\W^-5Z* +']H7W_/[=?\
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M%]_S^W7_ '^;_&C^T+[_ )_;K_O\W^-5Z* +']H7W_/[=?\ ?YO\:/[0OO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,"9?_BJ/^%:>$O^@4?_  )E_P#BJ/:Q#V;/GZBOH'_A6GA+_H%'_P "9?\
MXJC_ (5IX2_Z!1_\"9?_ (JCVL0]FSY^HKZ!_P"%:>$O^@4?_ F7_P"*H_X5
MIX2_Z!1_\"9?_BJ/:Q#V;/GZBOH'_A6GA+_H%'_P)E_^*H_X5IX2_P"@4?\
MP)E_^*H]K$/9L^?J*^@?^%:>$O\ H%'_ ,"9?_BJ/^%:>$O^@4?_  )E_P#B
MJ/:Q#V;/GZBOH'_A6GA+_H%'_P "9?\ XJC_ (5IX2_Z!1_\"9?_ (JCVL0]
MFSY^HKZ!_P"%:>$O^@4?_ F7_P"*H_X5IX2_Z!1_\"9?_BJ/:Q#V;/GZBOH'
M_A6GA+_H%'_P)E_^*H_X5IX2_P"@4?\ P)E_^*H]K$/9L^?J*^@?^%:>$O\
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M.#7H5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;*R+0*I"("&82*6;<3V(]J[SPYJ;ZUX:TW4Y%"R75LDKJ.@8CG'XT :E%%%
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MNJZK>R37*)(56(,2\C@X.0N0.V:[BH7EMEND1Y(A<,#L4D;R.^.]34 %%%%
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M_P"$O\,_]#%I'_@;'_\ %5J?9+;_ )]XO^^!1]DMO^?>+_O@4 9?_"7^&?\
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MJ:]U71I9+JW%M.?[05?,C!W!3AQT/?K5J76O!<UY9W<FMZ.T]FK+ _V]/D#
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M-I]J;.W)D)VQG&0?4_*.:AN?!VBWEAJ%E/;,T-]<?:I?WC!A+QAU/52,#&*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH **** "BF/+&C*KNJLYPH)P2?:G%E4@%@"W0$]:!V8M%%% @HHHH
M**** "BBB@ HHICRQQLJNZJ7.%!.,GVH!*X^BD+*I + %N ">M+0 4444 %%
M%% !1110 4444 %%,>6.,J'=5+'"ACC)]!3BRJ0"P!)P,GK0.S%HHHH$%%%%
M !1110 4444 %%%% !1110 444QY8XRH=U4L<*&.,GT% )7'T4A95(!8 DX
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M>)BQ(!&#A@,<U3UKP]KFJZE9W<>J6<:6RAE@>V+IYG=\$]?3/2L))KFM&_\
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M)WENEC8GJ0BG[V*2Q%+6^B_X%S2638E1C;63O=76EFEJ[VNV[6[D?_"OX/\
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M\*/^%?P?]#1XM_\ !P_^%==11RH+LY'_ (5_!_T-'BW_ ,'#_P"%'_"OX/\
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MAE$=VKYB8]<;>O\ GBI(_" 7PO?Z;+<+->7K&62=A@>9U!^@-=#_ ,(OJ?\
MT-=__P" MM_\;H_X1?4_^AKO_P#P%MO_ (W62I4K6UM:WI?L=<LRQ+L[I.Z;
M:23?+M=];?*_6YS5EX0G_P"$9U'3]0NTDO;YMTDZ9(&,;>N/2C2?#NH6K!;B
MRT*-5A:/SK:)A*Q*X!R>![UTO_"+ZG_T-=__ . MM_\ &Z/^$7U/_H:[_P#\
M!;;_ .-T>RI:?=^?^;'+-,5)34FO>=]MG9+2S5M$M-5Y%/P[IDVCZ#:V$[H\
MD0(9HR=IRQ/&<>M56T!I?&#ZO,()+8VHA6-AE@V0<XQCL>]:W_"+ZG_T-=__
M . MM_\ &Z/^$7U/_H:[_P#\!;;_ .-UHU!I+M_PQS?6JRJ3JIZSO?Y[V[&-
MXG\/2:RME-;?9O/LW++%<H3%(#U4@?2JZ^'KV70-3LGM])M)KI L?V-&51_O
M$C)_ 5T/_"+ZG_T-=_\ ^ MM_P#&Z/\ A%]3_P"AKO\ _P !;;_XW42ITVVW
MU_X8UAF&(A2C235HNZ^^_?OW3]3'U30;F^\/6&GQRPB6V>%G9B=IV8SCBF:I
MHNICQ!%K6CS6PG\GR)8;D-L9<Y!!'.?\*V_^$7U/_H:[_P#\!;;_ .-T?\(O
MJ?\ T-=__P" MM_\;JI1A)WUOI^&@H8ZO#LU[VC6CYM[_<O0Y0^#KU]):.2Z
M@>^GOUO)WY"<?PKQG\ZV[W29[GQ5IVJH\8AMHY$=23N);.,<8K0_X1?4_P#H
M:[__ ,!;;_XW1_PB^I_]#7?_ /@+;?\ QNE&G3CLNWX;#GF&)F[R:^TMNDDD
M_P $DNQSW_",W?\ 9/B"T\Z#?J4[21')PH/][C^6:JWOA._FO;693I]Q&EDE
MJR789A$P&"Z =?QQ75_\(OJ?_0UW_P#X"VW_ ,;H_P"$7U/_ *&N_P#_  %M
MO_C=2Z-)JVO]7_S9I#-,5!MIK7R_NJ/?M%=?S:.9T_PI>6<7AY'GMS_9DLKR
M[2WS!B2-O'OWQ2WWA&>_DUXO<1(+]XI(&&249,GYAC^6:Z7_ (1?4_\ H:[_
M /\  6V_^-T?\(OJ?_0UW_\ X"VW_P ;H=*DU:W]62_)(/[4Q?/[2ZOZ?WN?
M\_PT.?FT36]9T2[T_6KJR7S$183;(QPRG.YL^N!P*70=#O["\CDNK'1(DCC*
M^9:1,)&/3.3P/>M__A%]3_Z&N_\ _ 6V_P#C='_"+ZG_ -#7?_\ @+;?_&ZI
M0AS*>M_Z_KH0\PKNG*DDE&71*UM+.UGU\[EBBJ__  B^I_\ 0UW_ /X"VW_Q
MNC_A%]3_ .AKO_\ P%MO_C=;>T1YW*RQ15?_ (1?4_\ H:[_ /\  6V_^-T?
M\(OJ?_0UW_\ X"VW_P ;H]H@Y66**K_\(OJ?_0UW_P#X"VW_ ,;H_P"$7U/_
M *&N_P#_  %MO_C='M$'*RQ15?\ X1?4_P#H:[__ ,!;;_XW1_PB^I_]#7?_
M /@+;?\ QNCVB#E98HJO_P (OJ?_ $-=_P#^ MM_\;H_X1?4_P#H:[__ ,!;
M;_XW1[1!RLL457_X1?4_^AKO_P#P%MO_ (W1_P (OJ?_ $-=_P#^ MM_\;H]
MH@Y66**K_P#"+ZG_ -#7?_\ @+;?_&Z/^$7U/_H:[_\ \!;;_P"-T>T0<K+%
M%5_^$7U/_H:[_P#\!;;_ .-T?\(OJ?\ T-=__P" MM_\;H]H@Y60W6BZ9>S^
M?=6%O+-C'F.@+ ?6N8U3X>6,R6HTY?*V3AY1+.Y!3G('7!SCTKK?^$7U/_H:
M[_\ \!;;_P"-T?\ "+ZG_P!#7?\ _@+;?_&ZQG3I3^*)WX;'XO#-.E4:MTN[
M=>GS,;5K'Q#(LEGIDNF_8)(A&!<JY=!C!Y&0?QI-+T34]&ATJSM+V$V4 ;[6
M'3YI2<XV\' !QW%;7_"+ZG_T-=__ . MM_\ &Z/^$7U/_H:[_P#\!;;_ .-T
M<L.;FN[^OSMZ!]=J^R]E:-NNBU=FKONU=V>FNNYS6MZ+XDUN*73IKG3%T]Y-
MPE$;^:%SD#'3/^<UJ:EI$][;6>F)($TY0!<G<=\BKC"#V/<UH_\ "+ZG_P!#
M7?\ _@+;?_&Z/^$7U/\ Z&N__P# 6V_^-T*$-;W=_P! >.K6A%))1NU96U:M
M?U_76QSEUX7NI=5F>)[9;*6XAN,G/F1^6,;0,8P>.XKJZK_\(OJ?_0UW_P#X
M"VW_ ,;H_P"$7U/_ *&N_P#_  %MO_C=7#DA>W4QKXFK7454?P_\#_)%BBJ_
M_"+ZG_T-=_\ ^ MM_P#&Z/\ A%]3_P"AKO\ _P !;;_XW5^T1S<K+%4KC1]-
MN[I;FYL+>6=<8D>,%ACIS4O_  B^I_\ 0UW_ /X"VW_QNC_A%]3_ .AKO_\
MP%MO_C=)RB]T5"4X.\'9^3M^1R^KZ%XCUY!8WMUIBV(E#^;'&_FD \<'C/TQ
M5GQ3HFKZS9+IUC+8I984DS[_ #-R^X!&/PK?_P"$7U/_ *&N_P#_  %MO_C=
M'_"+ZG_T-=__ . MM_\ &ZP=*FTT[Z[Z]CT8YE7A*#BHKDNTN72[MK:^^G_
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M<A&UOP/-='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%<E/K6N:EXJU31]&DT^V338(FDDO+=YC+)("0
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MZ]+&W1116AR!1110 4444 %%%% !117/>(+W7-+L;_4;>731;6T>](I8G9G
MZY8, #Z<&IE+E5S6C2=6:@FDWW^[LSH:*RC-JE_:65Q8-:VRS1"27[3$TA7(
M!  #+^9-0^%]8N=9TR66[CB6>&XD@=H<['*G&5SSBESJ]BWAY*#G=::/75:M
M?FNYMT5QVH>)]0BGUH17&G6O]GD".WNHF:2?Y<@Y#C )X& :;K'B+4(2K+,E
M@\5@MX(70,9Y"<>7SVXQQSDU+K11T1R^K)K;7_)/MYK:Z[O1G9T5B6VHW>IZ
MSY=MB.RM5Q<M@$O*1_JP?1>I/K@5MUHG?8XZE-TVE+<****9F%%%% !1110
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M9>'3I-C=C3=*NRTUOIK,)@CJ5WKM.YB"<G')R:C_ +9^)G_0,\+_ /@3-_\
M$T?VS\3/^@9X7_\  F;_ .)HY6%T9^L>'X=3T759]$LO$$EVLMK+,]\9HY+I
M(V+;(O-PVX#/.!R1S6YHEII=SK1O;>T\2->I9.HGU1)U1%8C,8\W&6)P> 1Q
MUJG_ &S\3/\ H&>%_P#P)F_^)H_MGXF?] SPO_X$S?\ Q-'*PNC;^'-C<:;X
M#TVUNK9[:=5<O%(FU@2Y/(K'UK1O$VO^.WO-*U+^QX=,MQ!#-<6 G$S2?,Y0
M,0. %&1]*9_;/Q,_Z!GA?_P)F_\ B:/[9^)G_0,\+_\ @3-_\31RL+HSK'PI
MK4/AGQ'X:O&>YGMIQJ.F7J6_E1O*3YF% ) (<$8!_BJ&;0M:U_PAJNNW&FWD
M&JWU_#<M8DF.<6\! 6->F&.&8>Y%:_\ ;/Q,_P"@9X7_ / F;_XFC^V?B9_T
M#/"__@3-_P#$T<K"Z+FBV>EW.M->V]IXD:]2R=!/JB3JB*Q&8QYN,L3@\ CC
MK5+2(M>T+X-P)IMC-%JT2$F'R,RJ#)\Q"'JVTD@'J?6E_MGXF?\ 0,\+_P#@
M3-_\31_;/Q,_Z!GA?_P)F_\ B:.5A='/I97=I?\ B;4YIM;O+$Z%*@NM=B,*
ME\DE%&U2J\],#VXHTVWU!_L5KKLVM1W%WITEEHKW5I#'%$7BQM=HG9B^!QN"
M\ \9K9O;SXAZC9365YHWA2:VG0I)&]S,0RGJ#\M86E>'/%^CZBM]!I.AS3QD
MF'[5JMU,L.>/D# A>./7%'*PNC8\.Z98O;:#9ZEIOBH:A9R1J89O/:W@DC&-
MX<_NRG'&">".*]0KSO\ MGXF?] SPO\ ^!,W_P 31_;/Q,_Z!GA?_P "9O\
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M!,W_ ,31RL+H]$HKSO\ MGXF?] SPO\ ^!,W_P 31_;/Q,_Z!GA?_P "9O\
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ML_$S_H&>%_\ P)F_^)II-BN>B45YW_;/Q,_Z!GA?_P "9O\ XFC^V?B9_P!
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M/[TNP^7)^;.[D\8KOJ\[_MGXF?\ 0,\+_P#@3-_\31_;/Q,_Z!GA?_P)F_\
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M.-S 9P!UJW;6-MH_AY+/R#-#;PX,:Q[S)@<_+W)-<=_;/Q,_Z!GA?_P)F_\
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M6#C=>]-W](QT7WN_W'+IK^L:M=W2Z'8VKVMM(8C-<2E?,8=0 *L:1XLM;VW
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M*&C7?OOL8O+*"HU*DG*+C?31M65U>W1_*WF=U11178?/!1110 4444 %%%%
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MN5K3OZOUOIVM;=,****W/+"BBB@ HHHH *R-9NM:@8#2K*WF18R[R3R;>?0
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MEM_X.H__ (FO2:*7/(.5'FW]I?$+_H0[;_P=1_\ Q-']I?$+_H0[;_P=1_\
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M0[;_ ,'4?_Q-']I?$+_H0[;_ ,'4?_Q->DT4<\@LCS<:I\0QT\"6X_[C4?\
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M :0\0:M+907EOX;F>":!9LO=1(4R,X()[5<\,ZZOB708-52UEMHYRVQ)&!)
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MON/_ (BC_A<7@G_H)77_ (+[C_XBM_>_]YOSHWO_ 'F_.CV8<Q@?\+B\$_\
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MYOSJXPNKDMV,#_A<7@G_ *"5U_X+[C_XBC_A<7@G_H)77_@ON/\ XBM_>_\
M>;\Z-[_WF_.G[,7,8'_"XO!/_02NO_!?<?\ Q%'_  N+P3_T$KK_ ,%]Q_\
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M7!E7=]< 9K-0DIN2Z-[];I?E8]I8J@\/&E-NSARNRNTXS<MG;1I]RI#<SP>
M]2NK29XF?528Y4)&06'Z5K$WF@>)C#'J%U=1S:=+.RW#[OWB@G('0<CH*27Q
MG\.)M,337UBQ^QH05B42*!@Y'09J1_'?P^DU".^?7;-KF.,Q*Y\SA3U&,8/Y
M5*P\DE:6UOR:?YFL\VHSYDX:2<M++JHJ.N^G*V[;7TN<]>V[2>&=(U2;5KBX
MN+N[0R1/+N3.3T7MCIQ6E?S:QJ^NZXEM%J$DEK+Y5O\ 9[L1)#CH64_>R:C3
M6_A0CLZZAIX9F#YS+P0<\<<<^E3:AXD^&&J7C7=WJUD\[##LK2IN'OM S6?U
M:=MTOGY6W_$ZWG.%<K\K=N:UXK2\HM*R:TLN7T\F3BWU/5?$\.GWFH75KC3D
MEG6"3&7'';@<G)Q6G=#R_B1IY3J]C(K_ $!XJA!XW^'=M>+=PZW9).L(@##S
M.$'08QBJ4'C?P@?%=SJ]QXEL=@@6"W4;R0.K$_+Q6_LVK=^:_P M3@>.IU)-
M[15.2M9*\GIT]5N]$CH_&=W)%HGV*#/VC4)%MH\=>3R?RK;LK5+&R@M80 D*
M!%'T%<'=^-O!]YXELM1E\46'V6SC;RXMLFXR'^+[N,#BM?\ X6;X)_Z&.T_)
M_P#XFMH+WI2?I\E_P3SJU2*PU.C!WWD_5Z)?)+\2/P$\(M]5$K*+P7CF<,?F
MQV)]NOZUST+7-OI.K:KILLBVUIJHF18V(61,X88'4=*N7_B'X6ZG=FZN]4L7
MG;[S@RKN^N ,U?7QU\/$TUM.36K!;-D*&)5< @]?X:YO83<4KI<J=OZ^1ZW]
MJT(U)5HQ;<W&Z:5DENEO>^J6BLBK=:Y=W$7B'7;&XD-M;Q);VH!.T$XW/CID
M9I=*AUN&>"YCAOX[-[5S</=7BS!SLRK* ?E_"I;3QI\.+'3FT^WUBP6T?.Z(
MB1@V>N<@YJI9>(OA?ITYFM=6LT?:R EYFPIZ@9'%'L)W3YOQZZ_AK^ ?VGA5
M3G3A"RV5TG=**2OJM;W=]=6;/@>TN)-*@U6ZU"ZN)9HV01R2$HJAL#CUXZ^]
M4[^2_B^(\W]G6T5Q.VG!2LK[5 W#G^7%2V7Q \ Z=9QVEIK]G%!'G:@\PXR<
M]2,TP>._A\-3.I#7;/[88_*,O[S[O7&,8[5JZ/N0BG:W^1R_VC'ZU5K.-U)2
M25E;6UDTK::=#.O+/4?#VFZ3I"O([WUV[SK:2>63T(16/2K9&M6'AKQ!]I%W
M;P*@>T\ZX$DJ=,C>#FI-2\<?#O6+;[/?ZW8S1@Y (D!!]00,BJUOXI^&=K8W
M-E%K%F(+G_7*6E)?ZDC-8O#R3:B]+66OE8ZEFU.=->UC[_-=Z+7WD[K71V5M
MGIILV5]:T5U\,:??7&IWUQ/<S0,X:8[!N]%[8SQ]*UKN&2Z\5V?AUM1O(;.&
MR\W*S%99FR1RW4X _0U%<>./AY=64-G/KEF]O"5,:9E&TK]WD#/%1:IXO^&V
MLF,W^LV4K1_<<>8K#VR #BK>'LVX]UU>MD_UU)6;1E95+Z<]G:.G-;E:5DM$
MK?,SIM1U%-!NK:+49V^S:NEO#<[R6*\\$]ZUK[3+BW\1Z1HR:OJ'DS12M-)Y
MQWOW_#I^%0#Q9\-%TZ*P&K6(M8I!(D8\T88=#G&2?K5J7Q[\/Y]0AOY->LVN
MH%*QR?O/E!Z\8Q4QP[^T[[=7LKW_ *\BIYM2YOW<;+W^D=6TE%[=TVULF]+F
M-Y%^=$UV<ZU?[M)N"EL!*?7^(]6_&M35;P:B]O&K:I->?8%G>*SN!"D>1G<3
MW^E)_P )E\./LUY;_P!M6?E7K%[A<R_.3WZ<?A4%UXF^&-[+!)/JUDSP1B)#
MF4?(.BG Y'UJ?J\U&R?;J_/_ #7W%?VM0G-2G%Z-VLH]8Q71+>2;^=[[HAM[
MW4-3T[PFC:A<1274DT4LD;X9E!QSZG ZT3ZEJ&B6/B6SAOIY!:SPI#-,V]XQ
M(2#R?I5N'Q=\-K=;-8M8LE%DS-;@&7]V6.3VY_&GMXS^'#/>LVLV+&]P+C=Y
MA$F.G!''7M5/#SL[2U]7V2_-,;S;#<UO9WA>]K1W]IS?^DW7;I:Q-J:2>&O"
MU]=6.J75S.\,>/.F\S;N8 R+GH#D^W%)X>M]9AUBUE\B^CL)(#YQN[M9@[8R
M&7TJE8^)_AAIUO<06VJV"Q7 VRJWF/O'IR#1IOB;X9:3<BXLM8M(Y0I4,7E;
M /4#(-6J4O:*5[)=+[;_ 'F+S&A[&I3LY2E?5Q6MU9;-6MTW[[GH5%<I_P +
M-\$_]#':?D__ ,31_P +-\$_]#':?D__ ,379='SMCJZ*Y3_ (6;X)_Z&.T_
M)_\ XFC_ (6;X)_Z&.T_)_\ XFBZ"QU=%<I_PLWP3_T,=I^3_P#Q-'_"S?!/
M_0QVGY/_ /$T706.KHKE/^%F^"?^ACM/R?\ ^)H_X6;X)_Z&.T_)_P#XFBZ"
MQU=%<I_PLWP3_P!#':?D_P#\31_PLWP3_P!#':?D_P#\31=!8ZNBN4_X6;X)
M_P"ACM/R?_XFC_A9O@G_ *&.T_)__B:+H+'5T5RG_"S?!/\ T,=I^3__ !-'
M_"S?!/\ T,=I^3__ !-%T%CJZRK._O[R\EMKK19;:WPP$SRJP<=.@YY%9/\
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MK95#-,,Y1!GH2>*J6&J7.DWUS+=6B2SM-#%>2E\-'O'R(@_NJ,?4YJ:?Q[X
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M\$_]#':?D_\ \31_PLWP3_T,=I^3_P#Q-;71YMCJZ*Y3_A9O@G_H8[3\G_\
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M.6<(VE;7MY):O;7MIYW;ZRBN4_X6;X)_Z&.T_)__ (FC_A9O@G_H8[3\G_\
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M:M_R#I/JO\Q113/-.;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#:T+_5S_45KT44 8.N?\?B?]<Q_,UF444 %%%% !1110 4444 %%%% !111
D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
